Browse articles
J Carcinog2017,  16:1

Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis

1 Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, Texas, USA
2 Department of Hematology and Oncology, National Institute of Health, Bethesda, Maryland, USA
3 Department of Internal Medicine, Division of Oncology, University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA

Date of Submission23-Dec-2016
Date of Acceptance11-Apr-2017
Date of Web Publication29-May-2017

Correspondence Address:
Julie H Rowe
Department of Internal Medicine, Division of Oncology, University of Texas Health Science Center, McGovern Medical School, Houston, Texas
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jcar.JCar_9_16


Since the 1970s, the epidemic of hepatocellular carcinoma (HCC) has spread beyond the Eastern Asian predominance and has been increasing in Northern hemisphere, especially in the United States (US) and Western Europe. It occurs more commonly in males in the fourth and fifth decades of life. Among all cancers, HCC is one of the fastest growing causes of death in the US and poses a significant economic burden on healthcare. Chronic liver disease due to hepatitis B virus or hepatitis C virus and alcohol accounts for the majority of HCC cases. Incidence of nonalcoholic fatty liver disease has been on the risem and it has also been associated with the development of HCC. Its pathogenesis varies based on the underlying etiological factor although majority of cases develop in the setting of background cirrhosis. Carcinogenesis of HCC includes angiogenesis, chronic inflammation, and tumor macroenvironment and microenvironment. There is a significant role of both intrinsic genetic risk factors and extrinsic influences such as alcohol or viral infections that lead to the development of HCC. Understanding its etiopathogenesis helps select appropriate diagnostic tests and treatments.

Keywords: Carcinogenesis, epidemiology, etiology, hepatocellular carcinoma, pathogenesis

How to cite this article:
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog 2017;16:1

How to cite this URL:
Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis. J Carcinog [serial online] 2017 [cited 2021 Dec 2];16:1. Available from:

  Introduction Top

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver.[1] The global burden of cancer in 2012 was an all-time high of 14 million cases and is predicted to grow to 22 million over the next two decades.[2] Liver cancers have the seventh highest age-adjusted incidence rate in the world, with 0.8 million cases diagnosed for the year 2012.[3] Its most common etiological factor in the world is hepatitis B virus (HBV) infection. The development of cirrhosis is associated with high risk for developing HCC with most common risk factors including alcohol, viral hepatitis such as hepatitis C virus (HCV), and nonalcoholic fatty liver disease (NAFLD). Due to the wide prevalence of HCC, it carries a significant economic burden on society at large, especially in the East Asian countries where HBV infection is endemic. This is the third most common cause of cancer-related death in the world and seventh most common cause in the United States (US).[3],[4] Surveillance programs have also been implemented to screen for HCC in high-risk individuals, which is more cost-effective than the treatment of HCC.

The initial approach in the management of HCC is to determine if either surgical resection or liver transplantation is feasible. Since the majority of HCC cases develop in cirrhotic patients, surgical interventions can become challenging and the treatment has been directed toward liver transplantation. Certainly, prevention of the tumor seems to be a preferred strategy to tackle the shortage of donor organs. Hence, understanding the epidemiology, etiology, and pathogenesis of this economically burdening cancer is of prime significance for hepatologists and oncologists.

  Epidemiology Top

HCC is more common among males with a male:female ratio of 2.4 in its worldwide distribution.[5] The most common age at presentation is usually between 30 and 50 years.[6] HCC is predominant in Asian countries including China, Mongolia, Southeast Asia, and Sub-Saharan Western and Eastern Africa.[3] The prevalence of HCC in developed countries of the world is lower, except Japan, Italy, and France.

In the US surveillance, epidemiology, and end results (SEER) database program, HCC accounts for 65% of all cases of liver cancers.[7],[8] The incidence rate of HCC has increased from 1.4/100,000 cases/year between 1976–1980 to 6.2/100,000 cases reported in 2011.[8] There are almost two times higher incidence of HCC among dark-skinned males compared to light-skinned males; a similar trend is seen among females with two times higher incidence rate among dark-skinned when compared to light-skinned.[8] The 5-year survival trend has improved by >60% from 1975 to 2005.[9],[10]

A SEER-Medicare database, between 1991 and 1999, showed that the annual economic burden of HCC was 454.9 million US dollars.[11] This included healthcare cost and cost due to loss of productivity which was responsible for 89.2% and 10.8% of the total cost, respectively. Interestingly, HCC was most frequently found to be in individuals with lower socioeconomic status and among immigrant Hispanics, likely due to inadequate access to health care.[12]

  Etiology Top

HCC has a multitude of etiological risk factors, with some that have shown to have a strong association with development of HCC. Hepatotropic viruses such as HBV, HCV, and hepatitis D virus (HDV) have a strong association with development of HCC; thus, the worldwide distribution of HCC mirrors the distributions of such viral infections.[13] Various other associated risk factors are summarized in [Table 1]. Around 80%–90% of HCC cases occur in the setting of underlying cirrhosis.[14] In addition, there is an incremental effect of presence of more than one risk factor responsible for HCC as the presence of HBV/HCV and HBV/HDV coinfections increases risk of HCC by two to six folds. Similarly, alcohol abuse further increases this risk.[15],[16] Below, discussion will be focused on the most common risk factors for HCC.
Table 1: Risk Factors for Hepatocellular Carcinoma

Click here to view

Hepatitis-B virus

HBV is the most common cause for HCC worldwide accountable for an estimated 54% of all liver cancers.[17],[18] Chronic infection with HBV increases the relative risk for developing HCC 15–20-fold with a mortality rate of approximately 30%–50% among all cases of chronic HBV infection.[19],[20] Accordingly, regions endemic for chronic HBV infection have a similarly high incidence of HCC with >20 age cases per 100,000 males.[3],[21] In these endemic regions, transmission of virus is mostly by vertical and perinatal exposure, compared to developed countries where the transmission is through sexual and parental contact with infected blood like in case of intravenous drug abusers.[21] In the US, around 10%–16% of HCC cases are attributed to HBV.[22],[23] Approximately 10% of HIV-infected individuals are coinfected with chronic hepatitis B and are at higher risk of developing HCC than those with hepatitis B alone and in HIV patients with lower CD4+ counts.[24] A unique variant of HBV infection, occult HBV infection, occurs when the HBV-infected individual has the HBV viral particle but is tested negative for hepatitis B surface antigen; however, this can lead to cirrhosis and HCC.[25],[26]

Based on genetic sequencing, human HBV is currently grouped into 10 genotypes (A-J).[27] The most prevalent genotypes in the US are A and C, except Western US, where B and C are the predominant genotypes.[28] Patients with genotypes C and D are more likely to progress to cirrhosis and HCC, as well as have poorer response to treatment with interferon (IFN) and/or lamivudine (compared to genotypes A and B).[29],[30] Chronic HBV infection by genotype C puts one at risk of developing HCC, more than the other genotypes.[31]

Hepatitis-C virus

HCV is the second most common risk factor for HCC, with an estimated 10%–25% of all cases attributed to it around the world.[20],[32] In developed countries including Japan and the US, HCV is most common causative agent.[33],[34] Chronic HCV infection is associated with a 20–30-fold increased risk of developing HCC as compared to uninfected individuals. Approximately 2.5% of patients with chronic HCV infection develop HCC.[35] Even in the absence of an effective vaccine for HCV, implementation of a combination of laboratory measures such as screening of blood and blood products, public health initiatives such as identification and counseling, and treatment of infected and high-risk individuals can reduce and possibly even eliminate HCV infection rates globally.[36] Nearly 80% of the HIV-infected individuals who get infected with HCV develop chronic hepatitis C and this coinfection puts them at higher risk for developing HCC.[37],[38] In addition, HCV and HBV coinfection puts one at higher risk of developing HCC. In a study by Kruse et al., among the HCV-infected veteran population with or without additional HBV infection (detectable HBV DNA in serum or not), the incidence rate of developing HCC was higher in coinfected patients with and without detectable HBV DNA compared with HCV-monoinfected patients.[39] HCV viremia is associated with increased risk of developing HCC with studies from the last decade showing decreased risk of HCC by nearly 57%–75% among IFN-treated HCV patients.[22] With the newer HCV direct-acting agents, the impact on incidence of HCV-induced HCC is uncertain.


Alcohol-related cirrhosis is considered to be the third most common cause for HCC.[40] Alcohol works synergistically with hepatotropic viruses to increase the likelihood of developing HCC.[15] This effect was more pronounced in those individuals who consumed more than 60 g of alcohol per day. A study looking into the risk of developing HCC among heavy alcohol users with chronic HCV infection showed that individuals were at 2.3 (95% confidence interval: 1.67–3.26) times higher risk of developing HCC if they were heavy alcohol users (defined as alcohol use of 210–560 g/week).[41] Heavy alcohol in HBV patients increases the risk for HCC by almost three times; however, the differences can possibly due to different working definitions of heavy alcohol consumption. Alcohol can independently cause HCC by development of cirrhosis independent of the presence of viral hepatitis. HCC carcinogenesis induced by alcohol is associated with recurrent inflammation and cycles of hepatocyte necrosis and regeneration with oxidative stress, finally resulting in cirrhosis.[42]

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

NAFLD is the one of the most common causes of chronic liver disease in the US and has been consistently found to be causative of HCC, which occurs mainly in the setting of cirrhosis. The incidence has been on the rise in parallel with the rising rates of obesity, diabetes, and metabolic syndrome. Nonalcoholic steatohepatitis (NASH) has similar outcome as that of chronic HCV infection as demonstrated in a Japanese study comparing two groups, each having one underlying condition and having similar Child-Pugh class.[43] The 5-year risk of developing HCC in NASH group was 11.7% as compared to 30.4% in chronic HCV infection group. However, once HCC develops, the risk of mortality is same in both the groups. This has been demonstrated in an international, multicenter study which produced similar results.[44] Interestingly, NASH patients with no cirrhosis have no increased risk of HCC.[45]

  Pathogenesis of Hepatocellular Carcinoma Top

First, we will review the tumor macroenvironment and the major risk factors of HCC and its pathogenesis. Second, the molecular landscape and the tumor microenvironment (TME) will be described.

Tumor macroenvironment

Development of HCC is caused by intrinsic factors that are genetic mutations either inherited or acquired and extrinsic risk factors such as alcohol, smoking, and hepatotropic viruses-B, C, and D. It is widely accepted that both these factors play a significant role in the development of HCC. In the tumor macroenvironment, hepatocytes undergo malignant transformation through mechanisms that prevent tumor destruction and evade apoptosis and promote tumor proliferation and neovascularization. Cirrhosis induces carcinogenic changes and is found in 90% of patients diagnosed with HCC. In the remaining 10% patients, noncirrhotic mechanisms of carcinogenesis are responsible for malignant disease.[14]

In cirrhotic livers, metabolic and oxidative injury causes cyclical inflammation, necrosis, and repeated compensatory regeneration, and increased turnover of hepatocytes over a period of decades leads to accumulation of genetic errors and mutations such as point mutations, deletions in TP53, AXIN1, and CTNNB1; chromosomal gains; telomere erosion; and telomerase reactivation.[46] They also undergo activation of protooncogenes such as RAS-MAPK pathway and β-catenin, resulting in the formation of monoclonal populations of dysplastic hepatocytes in foci and nodules.[46],[47] It has been noted that the risk for HCC is greater when the cirrhosis is due to viral hepatitis compared to nonviral causes.[48] However, the risk of HCC in patients with cirrhosis due to hereditary hemochromatosis and primary biliary cholangitis (previously known as primary biliary cirrhosis) is comparable to those from viral causes.[49],[50]

Hepatitis B

HBV is an enveloped partially double-stranded, circular DNA virus, from the genus Orthohepadnaviridae of the family Hepadnaviridae. HBV has a tropism for hepatocytes, into which it enters through the sodium taurocholate cotransporting polypeptide receptor.[51] Following entry, its nucleocapsid is released into the cytosol and then is translocated along microtubules to the nucleus, wherein the HBV DNA is released from the nucleocapsid.[52] The HBV DNA is then converted into covalently closed circular DNA (cccDNA), which is organized into mini-chromosomes in the nucleus of the infected cell by binding to histones and nonhistones such as HBX protein and HBV core protein.[53],[54] This mini-chromosomal structure of cccDNA is hypothesized to be resistant to antiviral therapy and thus responsible for relapse following treatment with antiviral drugs.[55]

HBV initiates the process of hepatic carcinogenesis by integrating into the host genome.[56] It can also induce carcinogenic changes by modulating the expression of liver-specific micro-RNAs like miR-155.[57] Integration of HBV DNA fragments in the host genome alters telomerase reverse transcriptase, which regulates expression of host genes.[58] Other proposed mechanisms include secretion of viral oncogenic proteins such as HBX and mutant pre-S2/S proteins.[59],[60] HBX in particular has been closely studied and is now considered to be essential for HBV replication. It activates a wide range of targets such as RAS/MAPK1 and PI3k/AKT pathway and augments its invasive potential of HBx-infected cells.[61],[62] It can act as a transactivator of other oncogenic genes such as c-myc protooncogene and it is self-generating by promoting HBV replication.[63],[64]

Chronic liver damage induces fibrogenesis and inflammatory markers induce fibrosis in the liver leading to cirrhosis and presence of both cirrhosis and HBV infection further increases the risk of developing HCC.[14] Interestingly, noncirrhotic HBV-infected individuals have also shown to develop HCC. In a study of 44 patients with HBV-positive noncirrhotic HCC individuals as compared to chronic HBV carriers without HCC for risk factors of HCC, Liu et al. demonstrated a higher risk of developing HCC associated with male gender, higher viral loads, or BCP T1762/A1764 mutation. Among patients diagnosed with HCC, the HBV cirrhotics had a higher viral load than HBV noncirrhotics.[65]

Hepatitis C

The virus tends to cause chronic infection in 70%–80% of the infected cases in compared to HBV which induces chronicity in only 10% of infected cases.[66] HCV carcinogenesis is mediated by the viral-induced factors and host-induced immunologic response. The viral replication does not lead to cellular death, but the virus tends to harbor in the endoplasmic reticulum of the hepatocytes, replicating its RNA and inducing synthesis of its nonstructural proteins such as NS2, NS3, NS4A, NS5A, and NS5B, which form the RNA-dependent RNA polymerase and the viral envelope proteins.[42] Unlike HBV, HCV is a RNA virus that does not integrate its genomic material into the host genome. However, the current studies show that HCV gene products such as core protein, NS3, NS4B, and NS5A in tissue culture models can potentially lead to cellular transformation, but in vivo studies are yet to confirm these findings. HCV gene products such as core proteins alter the MAPK signaling pathway, thereby affecting cellular proliferation.[67] The NS5A protein inhibits the p53 pathway which affects cell cycles, cellular proliferation, and antitumor mechanisms.[68] The newer direct-acting antiviral agents are designed to be directed against HCV viral proteases. HCV viremia is associated with increased risk of developing HCC with studies from the last decade showing decreased risk of HCC by nearly 57%–75% among IFN-treated HCV patients.[22] With the newer direct-acting agents, overall incidence of HCV-induced HCC is likely to be significantly reduced.

HCV replication induces a unique immunologic host response within every individual. This response is mediated by factors such as tumor necrosis factor (TNF-α) and IFNs and results in cell injury, death, and regeneration. The hepatocytes undergo several such cycles of cellular death and regeneration, leading to scarring and fibrosis. The severity of fibrosis has been linked with the probability of harboring HCC although there have been studies that showed development of HCC, even in the absence or with low-grade fibrosis.[22] Furthermore, oxidative stress on the hepatocytes by reactive oxygen species (ROS) formation induced by the virus and host immune response leads to cell death and regeneration, subsequently leading to mutations in the hepatocytes and thereby development of HCC.


Ethyl alcohol or ethanol is one of the oldest known chemical carcinogens known to cause HCC.[40],[42] Ethanol's metabolites, acetaldehyde and various ROS, produced by action of alcohol dehydrogenase and cytochrome P450 2E1 (CYP2E1), possess the capacity to induce chronic oxidative stress and chronic inflammation, leading to cirrhosis and eventually to malignancy.[69],[70] In chronic liver injury from alcohol exposure, overproduction of ROS disrupts the interactions of DNA, RNA, lipids, and proteins, resulting in genomic instability and insufficient repair pathways.[69] Genetic variations in these enzymes are associated with differences in susceptibility to HCC.[71] Additional mechanisms proposed include iron overload, decreased vitamin A (retinoid acid) levels and downregulation of S-adenosyl methionine.[69] A comparison of whole exome sequencing of HCC tumors from European and Asian cohorts demonstrated differences based on risk factors.[72] Alcohol was the major risk factor in the European cohort and was associated with inactivation of chromatin remodelers; however, in the Asian cohort, where HBV and HCV were the major etiological risk factors, mutations in chromatin remodeling were also present, but to a lesser extent. Further, p53 was also commonly detected in both cohorts but varied from 10% to 60% in the Asian/African versus 10%–20% in Western countries.[73],[74]

Molecular landscape of hepatocellular carcinoma

The pathogenesis of etiologies of HCC has provided further understanding of the mutational background and molecular landscape of HCC. Further, techniques such as next-generation sequencing of HCC tumors have provided insight on the genetic landscape. Similar to other solid tumors, somatic mutations in HCC include C:G > T:A transitions. In addition, there are T:A > C:G transitions and C:G > A:T transversions that are unique to HCC.[75] The C:G > A:T transversions are more common in HBV-related HCC.[75] In early hepatocarcinogenesis, there is loss of insulin-like growth factor 2 receptor, resulting in unchecked proliferation.[34] CTNNB1 is most commonly mutated oncogene in HCC (~30%) but varies in frequency based on the etiology of HCC and more often mutated in HCV-related or nonviral-related HCC.[51] Alternately, TP53 is the most commonly mutated tumor suppressor gene and occurs more frequently in HBV-related HCC.[76] Other well-described pathways of HCC include the RAS/PI3K pathways. Whole exome sequencing has also revealed other novel pathways involving the chromatin remodeling, histone methylation, and oxidative stress.[76]

Tumor microenvironment

The TME is a complex network of tumor cells and stromal cells including angiogenic cells, immune cells, and cancer-related fibroblastic cells, in which signaling pathways and production of molecules and soluble factors promote carcinogenesis.[77] During chronic hepatic injury, fibrosis results from deposition of extracellular matrix (ECM), which leads to poor oxygen exchange. Hypoxia is further propagated with the secretion of pro-angiogenic factors by stromal cells and hypoxia-inducible factor-1α (HIF-1α) production is induced.[78] Excess ECM production and decreased turnover leads to a fibrotic environment and stimulates tumor growth, survival, and proliferation through enhanced integrin signaling.[77] Tumor-associated fibroblasts (TAFs) secrete factors that promote tumor growth and angiogenesis and are involved in cross-talk with cancer cells.[77],[78] Immune cells, especially tumor infiltrating lymphocytes (TILs), are important for antitumor response; however, there is a predominance of circulating regulatory T-cells and myeloid-derived suppressive cells that dampen the immune response.[77] In addition, tumor-associated macrophages (TAMs) release chemokines and growth factors that suppress antitumor immunity.

Angiogenesis plays a key role in the carcinogenesis of HCC. HCC is characterized by an excess of angiogenic factors produced by tumor cells, vascular endothelial cells, immune cells, and surrounding TME. This creates a vascular network composed of leaky and abnormal vasculature resulting in hypovascular regions within the tumor, which promotes hypoxia and necrosis. Vascular endothelial growth factor (VEGF) is an important mediator in hepatocarcinogenesis and regulated by oncogenic gene mutations, hormones, and cytokines. Its overexpression results in leaky vessels and abnormal vascular structure and function. This creates a hypoxic and acidotic environment, which further stimulates VEGF overexpression. In addition, VEGF acts on the surrounding stromal environment consisting of hepatic stellate cells and Kupffer cells through VEGR receptors.[79] HIF-1α is stimulated by hypoxic conditions and play a synergistic role with other angiogenic factors, especially VEGF in counteracting apoptosis and promoting cell proliferation.[77],[78] In addition, hypoxia induces autophagy which generates energy for tumor cells and its surrounding environment through catabolic breakdown of cellular elements to help promote cancer survival.[77] The TME is also composed of the ECM and stromal cells that releases VEGF. Other angiogenic molecules include angiopoietin (ANGPT) 1, ANGPT2, and basic fibroblast growth factor (bFGF), which promote dysfunctional vascular networks in HCC.[79] Ang-2 boosts the effect of VEGF on endothelial cells, which produce molecules that disrupt the basement membrane, further augmenting a hypoxic TME. bFGF and VEGF act synergistically to induce angiogenesis, and platelet-derived endothelial cell growth factor promotes cell migration and new vessel maturation.[77] These factors as well as transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF), endothelial growth factor (EGF), interleukin 4 (IL-4), IL-6, and IL-8 are elevated in HCC patients. Moreover, the PI3K/AKT pathways are activated in endothelial cells, and conversely, Dll4/Notch pathway is an antiangiogenic pathway, which may be downregulated in HCC.[77]

In cirrhosis, chronic inflammation mediated by persistent cytokine and chemokine production is a central process in development of dysplastic nodules and HCC.[34] TGF-β, HGF, and EGF are key growth factors that regulate the immune and inflammatory process.[77],[78] There are increased Th2-like cytokines (IL-4, IL-5, IL-8, and IL10) compared to Th1-like cytokines (IL-1α, IL-1 β, IL-2, TNF-α) in a phenotype of more aggressive and metastatic HCC.[77] The role of chemokines (i.e., CXCL12, CX3CL1, and CCL20) is to regulate cell trafficking into and out of the TME by binding to a family of receptors (i.e., CCR, CXCR, CX3CR, and XCR).[77] The receptors are found on inflammatory, endothelial, and epithelial cells. For example, the CXCL12-CXCR4 axis regulates angiogenesis.[77] Interactions with these receptors with cells of the TME mediate cancer progression, invasion, and metastasis.[78]

In summary, the epidemiology, etiology, and pathogenesis of HCC are complex. Further understanding of HCC and the etiological influence are imperative as this can provide improved strategies on the treatment of HCC based on its risk factors and pathways implicated by hepatocarcinogenesis.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

  References Top

Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: Adami HO, Hunter D, and Trichopoulos D, editors. Textbook of Cancer Epidemiology. 2nd ed. Oxford University Press, New York; 2008.  Back to cited text no. 1
Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer; 2014.  Back to cited text no. 2
World Health Organization, I.A.f.R.o.C. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from:  Back to cited text no. 3
SEER Cancer Statistics Factsheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute; 2014. Available from: [Last accessed on 2017 Apr].  Back to cited text no. 4
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.  Back to cited text no. 5
Kumar V, Abbas AK, Fausto N, Robbins SL, and Cotran RS. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia:Elsevier Saunders; 2004.  Back to cited text no. 6
Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: Consider the population. J Clin Gastroenterol 2013;47 Suppl:S2.  Back to cited text no. 7
El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.  Back to cited text no. 8
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.  Back to cited text no. 9
Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015;61:191-9.  Back to cited text no. 10
Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009;50:89-99.  Back to cited text no. 11
Shebl FM, Capo-Ramos DE, Graubard BI, McGlynn KA, Altekruse SF. Socioeconomic status and hepatocellular carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2012;21:1330-5.  Back to cited text no. 12
El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.  Back to cited text no. 13
Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. Hepatology 2012;56:769-75.  Back to cited text no. 14
Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.  Back to cited text no. 15
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127 5 Suppl 1:S35-50.  Back to cited text no. 16
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.  Back to cited text no. 17
Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33.  Back to cited text no. 18
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.  Back to cited text no. 19
Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, et al. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol 2011;29:3643-50.  Back to cited text no. 20
Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127 5 Suppl 1:S5-16.  Back to cited text no. 21
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1.  Back to cited text no. 22
Dorfman JD, Schulick R, Choti MA, Geschwind JF, Kamel I, Torbenson M, et al. Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States. World J Gastroenterol 2007;13:781-4.  Back to cited text no. 23
Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005;19:593-601.  Back to cited text no. 24
Yotsuyanagi H, Shintani Y, Moriya K, Fujie H, Tsutsumi T, Kato T, et al. Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: Frequent involvement of hepatitis B virus. J Infect Dis 2000;181:1920-8.  Back to cited text no. 25
Chen CH, Changchien CS, Lee CM, Tung WC, Hung CH, Hu TH, et al. A study on sequence variations in pre-S/surface, X and enhancer II/core promoter/precore regions of occult hepatitis B virus in non-B, non-C hepatocellular carcinoma patients in Taiwan. Int J Cancer 2009;125:621-9.  Back to cited text no. 26
Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol 2009;83:10538-47.  Back to cited text no. 27
Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Hepatitis B virus genotypes in the United States: Results of a nationwide study. Gastroenterology 2003;125:444-51.  Back to cited text no. 28
Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T, et al. Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 2005;54:1009-13.  Back to cited text no. 29
Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-a2b: Relation to response and HBV genotype. Antivir Ther 2012;17:9-17.  Back to cited text no. 30
Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008;26:177-82.  Back to cited text no. 31
Tanaka H, Tsukuma H, Yamano H, Oshima A, Shibata H. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. Int J Cancer 2004;112:1075-80.  Back to cited text no. 32
Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: Projection to other countries in the foreseeable future. Oncology 2002;62 Suppl 1:8-17.  Back to cited text no. 33
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.  Back to cited text no. 34
Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52.  Back to cited text no. 35
Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21 Suppl 1:60-89.  Back to cited text no. 36
Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010;85:303-15.  Back to cited text no. 37
Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22:2135-41.  Back to cited text no. 38
Kruse RL, Kramer JR, Tyson GL, Duan Z, Chen L, El-Serag HB, et al. Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology 2014;60:1871-8.  Back to cited text no. 39
Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85.  Back to cited text no. 40
Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: A meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9.  Back to cited text no. 41
Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: From genes to environment. Nat Rev Cancer 2006;6:674-87.  Back to cited text no. 42
Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.  Back to cited text no. 43
Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. Hepatology 2011;54:1208-16.  Back to cited text no. 44
Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009;44:1236-43.  Back to cited text no. 45
Jhunjhunwala S, Jiang Z, Stawiski EW, Gnad F, Liu J, Mayba O, et al. Diverse modes of genomic alteration in hepatocellular carcinoma. Genome Biol 2014;15:436.  Back to cited text no. 46
Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.  Back to cited text no. 47
Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.  Back to cited text no. 48
Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, et al. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-9.  Back to cited text no. 49
Caballería L, Parés A, Castells A, Ginés A, Bru C, Rodés J. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001;96:1160-3.  Back to cited text no. 50
Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, et al. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013;87:7977-91.  Back to cited text no. 51
Rabe B, Delaleau M, Bischof A, Foss M, Sominskaya I, Pumpens P, et al. Nuclear entry of hepatitis B virus capsids involves disintegration to protein dimers followed by nuclear reassociation to capsids. PLoS Pathog 2009;5:e1000563.  Back to cited text no. 52
Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001;307:183-96.  Back to cited text no. 53
Tang H, Delgermaa L, Huang F, Oishi N, Liu L, He F, et al. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J Virol 2005;79:5548-56.  Back to cited text no. 54
Lewin S, Walters T, Locarnini S. Hepatitis B treatment: Rational combination chemotherapy based on viral kinetic and animal model studies. Antiviral Res 2002;55:381-96.  Back to cited text no. 55
Imai M, Hoshi Y, Okamoto H, Matsui T, Tsurimoto T, Matsubara K, et al. Free and integrated forms of hepatitis B virus DNA in human hepatocellular carcinoma cells (PLC/342) propagated in nude mice. J Virol 1987;61:3555-60.  Back to cited text no. 56
Wang B, Majumder S, Nuovo G, Kutay H, Volinia S, Patel T, et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology 2009;50:1152-61.  Back to cited text no. 57
Toh ST, Jin Y, Liu L, Wang J, Babrzadeh F, Gharizadeh B, et al. Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations. Carcinogenesis 2013;34:787-98.  Back to cited text no. 58
Lin CM, Wang GM, Jow GM, Chen BF. Functional analysis of hepatitis B virus pre-s deletion variants associated with hepatocellular carcinoma. J Biomed Sci 2012;19:17.  Back to cited text no. 59
Su IJ, Wang LH, Hsieh WC, Wu HC, Teng CF, Tsai HW, et al. The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci 2014;21:98.  Back to cited text no. 60
Wang WH, Hullinger RL, Andrisani OM. Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis. J Biol Chem 2008;283:25455-67.  Back to cited text no. 61
Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: Involvement of invasive potential. FASEB J 2004;18:1123-5.  Back to cited text no. 62
Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997;14:395-404.  Back to cited text no. 63
Benhenda S, Cougot D, Buendia MA, Neuveut C. Hepatitis B virus X protein molecular functions and its role in virus life cycle and pathogenesis. Adv Cancer Res 2009;103:75-109.  Back to cited text no. 64
Liu CJ, Chen BF, Chen PJ, Lai MY, Huang WL, Kao JH, et al. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: A case-control study. J Infect Dis 2006;194:594-9.  Back to cited text no. 65
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.  Back to cited text no. 66
Hino O, Kajino K, Umeda T, Arakawa Y. Understanding the hypercarcinogenic state in chronic hepatitis: A clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 2002;37:883-7.  Back to cited text no. 67
Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001;75:1401-7.  Back to cited text no. 68
Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007;7:599-612.  Back to cited text no. 69
Abnet CC. Carcinogenic food contaminants. Cancer Invest 2007;25:189-96.  Back to cited text no. 70
Väkeväinen S, Tillonen J, Agarwal DP, Srivastava N, Salaspuro M. High salivary acetaldehyde after a moderate dose of alcohol in ALDH2-deficient subjects: Strong evidence for the local carcinogenic action of acetaldehyde. Alcohol Clin Exp Res 2000;24:873-7.  Back to cited text no. 71
Teufel A, Marquardt JU, Galle PR. Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/ß-catenin. J Hepatol 2013;58:622-4.  Back to cited text no. 72
Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 2012;44:694-8.  Back to cited text no. 73
Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012;44:760-4.  Back to cited text no. 74
Li S, Mao M. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett 2013;340:247-53.  Back to cited text no. 75
Nakagawa H, Shibata T. Comprehensive genome sequencing of the liver cancer genome. Cancer Lett 2013;340:234-40.  Back to cited text no. 76
Hernandez-Gea V, Toffanin S, Friedman SL, Llovet JM. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013;144:512-27.  Back to cited text no. 77
Wu SD, Ma YS, Fang Y, Liu LL, Fu D, Shen XZ. Role of the microenvironment in hepatocellular carcinoma development and progression. Cancer Treat Rev 2012;38:218-25.  Back to cited text no. 78
Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: Possible targets and future directions. Nat Rev Clin Oncol 2011;8:292-301.  Back to cited text no. 79


  [Table 1]

This article has been cited by
1 Adoption of single agent anticancer therapy for advanced hepatocellular carcinoma and impact of facility type, insurance status, and income on survival: Analysis of the national cancer database 2004–2014
Aman Opneja, Gino Cioffi, Asrar Alahmadi, Nelroy Jones, Tin-Yun Tang, Nirav Patil, David L. Bajor, Joel N. Saltzman, Amr Mohamed, Eva Selfridge, Ankit Mangla, Jill Barnholtz-Sloan, Richard T. Lee
Cancer Medicine. 2021; 10(13): 4397
[Pubmed] | [DOI]
2 Targeting molecular signal transduction pathways in hepatocellular carcinoma and its implications for cancer therapy
Ishfaq Hassan Mir, Shreyoshi Guha, Jajnasenee Behera, Chinnasamy Thirunavukkarasu
Cell Biology International. 2021; 45(11): 2161
[Pubmed] | [DOI]
3 A case report on a large, peduncular intra-abdominal hepatocellular carcinoma extending into the retroperitoneum
Dana M. Omer, Jordan Dozier, Zongxian Cao, Hongfa Zhu, Donald A. McCain
Clinical Case Reports. 2021; 9(3): 1288
[Pubmed] | [DOI]
4 Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells
Zhuo Liu, Shaojie Li, Tiexiang Ma, Jian Zeng, Xin Zhou, Huanyu Li, Min Tang, Xiang Liu, Feng Li, Bin Jiang, Ming Zhao, Ying Chen
Immunity, Inflammation and Disease. 2021; 9(1): 144
[Pubmed] | [DOI]
5 Biomimetic synthesis of silver nanoparticles for treatment of N- Nitrosodiethylamine-induced hepatotoxicity
Asha Singh, Mohd Yaqoob Dar, Durga P. Nagar, Rajesh S. Tomar, Sadhana Shrivastava, Sangeeta Shukla
Journal of Biochemical and Molecular Toxicology. 2021;
[Pubmed] | [DOI]
6 Inhibitory and ameliorative effect of heliomycin derived from actinomycete on induced hepatocellular carcinoma in rats
Ahmed S. Alazzouni, Abdulla A. Mahmoud, Mohamed M. Omran, Ehab A. Essawy, Mohga S. Abdalla, Mohamed S. Abdelfattah
Naunyn-Schmiedeberg's Archives of Pharmacology. 2021; 394(6): 1091
[Pubmed] | [DOI]
7 How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?
Islam H. Zaki, Erin Shropshire, Shuaiqi Zhang, Dong Xiao, Benjamin Wildman-Tobriner, Daniele Marin, Rajan T. Gupta, Alaattin Erkanli, Redon C. Nelson, Mustafa R. Bashir
Abdominal Radiology. 2021; 46(3): 969
[Pubmed] | [DOI]
8 Comparison of low kVp CT and dual-energy CT for the evaluation of hypervascular hepatocellular carcinoma
Jeongin Yoo, Jeong Min Lee, Jeong Hee Yoon, Ijin Joo, Eun Sun Lee, Sun Kyung Jeon, Siwon Jang
Abdominal Radiology. 2021; 46(7): 3217
[Pubmed] | [DOI]
9 Post-hepatectomy liver failure after hepatic resection for hepatocellular carcinoma: a single center experience
Ahmed Shehta, Ahmed Farouk, Amgad Fouad, Ahmed Aboelenin, Ahmed Nabieh Elghawalby, Rami Said, Mohamed Elshobary, Ayman El Nakeeb
Langenbeck's Archives of Surgery. 2021; 406(1): 87
[Pubmed] | [DOI]
10 TRIM37 overexpression is associated with chemoresistance in hepatocellular carcinoma via activating the AKT signaling pathway
Guosheng Tan, Binhui Xie, Na Yu, Jianwen Huang, Bing Zhang, Fangzeng Lin, Heping Li
International Journal of Clinical Oncology. 2021; 26(3): 532
[Pubmed] | [DOI]
11 REC8 promotes tumor migration, invasion and angiogenesis by targeting the PKA pathway in hepatocellular carcinoma
Jing Han, Yun Bai, Jia Wang, Xiao-li Xie, Ai-di Li, Qian Ding, Zi-jin Cui, Jie Yin, Xiao-yu Jiang, Hui-qing Jiang
Clinical and Experimental Medicine. 2021; 21(3): 479
[Pubmed] | [DOI]
12 Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis
Antonio Giovanni Solimando, Nicola Susca, Antonella Argentiero, Oronzo Brunetti, Patrizia Leone, Valli De Re, Rossella Fasano, Markus Krebs, Elisabetta Petracci, Irene Azzali, Oriana Nanni, Nicola Silvestris, Angelo Vacca, Vito Racanelli
Clinical and Experimental Medicine. 2021;
[Pubmed] | [DOI]
13 Association of MTHFR and TYMS gene polymorphisms with the susceptibility to HCC in Egyptian HCV cirrhotic patients
Hany M. M. Abdel Allah, Walid E. Zahran, Samir A. El-Masry, Mahmoud El-Bendary, Ahmed F. Soliman
Clinical and Experimental Medicine. 2021;
[Pubmed] | [DOI]
14 The expanding role of CDR1-AS in the regulation and development of cancer and human diseases
Hanieh Azari, Pegah Mousavi, Elham Karimi, Fatemeh Sadri, Mahboobeh Zarei, Milad Rafat, Mohammad Shekari
Journal of Cellular Physiology. 2021; 236(2): 771
[Pubmed] | [DOI]
15 Apoptotic effect of compound K in hepatocellular carcinoma cells via inhibition of glycolysis and Akt/ mTOR / c-Myc signaling
Nari Shin, Hyo-Jung Lee, Deok Yong Sim, Eunji Im, Ji Eon Park, Woon Yi Park, Ah Reum Cho, Bum Sang Shim, Sung-Hoon Kim
Phytotherapy Research. 2021; 35(7): 3812
[Pubmed] | [DOI]
16 Potential anticancer effects of cyclo(-Pro-Tyr) against N-diethyl nitrosamine induced hepatocellular carcinoma in mouse through PI3K/AKT signaling
Gayathri Karanam, Madan Kumar Arumugam
Environmental Toxicology. 2021;
[Pubmed] | [DOI]
17 Hsa-circRNA-103809 Promotes Hepatocellular Carcinoma Development via MicroRNA-1270/PLAG1 Like Zinc Finger 2 Axis
Yajuan Cao, Qingsong Tao, Xiaoming Kao, Xinhua Zhu
Digestive Diseases and Sciences. 2021; 66(5): 1524
[Pubmed] | [DOI]
18 Determinants of Hepatitis B Virus (HBV) Infection Among University Students in Central Bangladesh
Md. Rabiul Islam, Nusrat Hosain Sheba, Md. Torikul Islam, Md. Mostafizur Rahman, Sharmin Hossain, Md. Anower Hussain, Shariful Islam, ABM Alauddin Chowdhruy, Tajuddin Sikder, Moniruddin Chowdhury, Rine Christopher Reuben, Faisal Muhammad
Journal of Community Health. 2021;
[Pubmed] | [DOI]
19 Psychometric validation of the EORTC QLQ-HCC18 in patients with previously treated unresectable hepatocellular carcinoma
Daniel Serrano, Lauren Podger, Gisoo Barnes, James Song, Boxiong Tang
Quality of Life Research. 2021;
[Pubmed] | [DOI]
20 Prolonged hypoxia switched on cancer stem cell-like plasticity in HepG2 tumourspheres cultured in serum-free media
Ain Zubaidah Ayob, Thamil Selvee Ramasamy
In Vitro Cellular & Developmental Biology - Animal. 2021;
[Pubmed] | [DOI]
21 Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis
Hamid Ceylan
Medical Oncology. 2021; 38(6)
[Pubmed] | [DOI]
22 HBx promotes hepatocarcinogenesis by enhancing phosphorylation and blocking ubiquitinylation of UHRF2
Fengjuan Cheng, Guanhua Qian, Xianyun Fang, Jingjie Sun, Siyuan Chen, Rongjuan Chen, Shangjing Liu, Zhaodi Li, Kejia Wu, Shiming Jiang, Yong Chen, Ni Tang, Juan Chen, Changzhu Duan
Hepatology International. 2021; 15(3): 707
[Pubmed] | [DOI]
23 Antibody–drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance
M. Murali, A. R. Kumar, B. Nair, K. Pavithran, A. R. Devan, G. K. Pradeep, L. R. Nath
Clinical and Translational Oncology. 2021;
[Pubmed] | [DOI]
24 Combined inhibition of AURKA and HSF1 suppresses proliferation and promotes apoptosis in hepatocellular carcinoma by activating endoplasmic reticulum stress
Zetian Shen, Li Yin, Han Zhou, Xiaoqin Ji, Changchen Jiang, Xixu Zhu, Xia He
Cellular Oncology. 2021; 44(5): 1035
[Pubmed] | [DOI]
25 GLP-1 reduces the migration of hepatocellular carcinoma cells via suppression of the stress-activated protein kinase/c-Jun N-terminal kinase pathway
Noriko Yamada, Rie Matsushima-Nishiwaki, Kaido Kobayashi, Junko Tachi, Osamu Kozawa
Archives of Biochemistry and Biophysics. 2021; 703: 108851
[Pubmed] | [DOI]
26 miR-93 regulates liver tumor initiating cells expansion and predicts chemotherapeutic response of patients
Jun Li, Xingyang Zhong, Xinjun Wang, Feng Xu, Jiamei Yang, Junhua Lu, Caifeng Liu, Jiongjiong Lu
Archives of Biochemistry and Biophysics. 2021; 703: 108871
[Pubmed] | [DOI]
27 Acquisition of mesenchymal-like phenotypes and overproduction of angiogenic factors in lenvatinib-resistant hepatocellular carcinoma cells
Junjie Ao, Tetsuhiro Chiba, Shuhei Shibata, Akane Kurosugi, Na Qiang, Yaojia Ma, Motoyasu Kan, Terunao Iwanaga, Takafumi Sakuma, Hiroaki Kanzaki, Kengo Kanayama, Ryuta Kojima, Yuko Kusakabe, Masato Nakamura, Tomoko Saito, Ryo Nakagawa, Takayuki Kondo, Sadahisa Ogasawara, Eiichiro Suzuki, Ryosuke Muroyama, Jun Kato, Naoya Mimura, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Biochemical and Biophysical Research Communications. 2021; 549: 171
[Pubmed] | [DOI]
28 Bioactive components and mechanisms of poplar propolis in inhibiting proliferation of human hepatocellular carcinoma HepG2 cells
Hui Liu, Junya Li, Wenwen Yuan, Shengyu Hao, Meng Wang, Fei Wang, Hongzhuan Xuan
Biomedicine & Pharmacotherapy. 2021; 144: 112364
[Pubmed] | [DOI]
29 Examining the gut-liver axis in liver cancer using organoid models
Dmitrii Shek, Dishen Chen, Scott A. Read, Golo Ahlenstiel
Cancer Letters. 2021; 510: 48
[Pubmed] | [DOI]
30 Mimics of hepatocellular carcinoma: a review and an approach to avoiding histopathological diagnostic missteps
Dauod Arif, Tetyana Mettler, Oyedele A. Adeyi
Human Pathology. 2021; 112: 116
[Pubmed] | [DOI]
31 LncAY controls BMI1 expression and activates BMI1/Wnt/ß-catenin signaling axis in hepatocellular carcinoma
Mei Hua Chen, Li Sheng Fu, Fan Zhang, Ying Yang, Xing Zhong Wu
Life Sciences. 2021; 280: 119748
[Pubmed] | [DOI]
32 ZMYND8 promotes the growth and metastasis of hepatocellular carcinoma by promoting HK2-mediated glycolysis
Changwei Dou, Huanye Mo, Tianxiang Chen, Jie Liu, Yuqun Zeng, Shuangshuang Li, Cheng Guo, Chengwu Zhang
Pathology - Research and Practice. 2021; 219: 153345
[Pubmed] | [DOI]
33 Levels of aflatoxins, heavy and trace metal contaminants in two non-alcoholic beverages, Asaana and Nmedaa, and two alcoholic beverages, Burukutu and Pito produced by the informal sector in Ghana
C.B. Osei, C. Tortoe, E. Kyereh, R. Adjei-Mensah, P-N.T. Johnson, D. Aryee
Scientific African. 2021; 12: e00813
[Pubmed] | [DOI]
34 MicroRNA-4317 suppresses the progression of hepatocellular carcinoma by targeting ZNF436-mediated PI3K/AKT signaling pathway
Li Zhang, Shuai Chang, Yao Zhao, Gang Cao, Di Zhang
Tissue and Cell. 2021; : 101696
[Pubmed] | [DOI]
35 Long-term persistent immunogenicity after successful standard and triple-dosed hepatitis B vaccine in hemodialysis patients: A 3-year follow-up study in China
Tian Yao, Zhihong Shao, Lina Wu, Shuang Dong, Linying Gao, Yuanting Wu, Xiaohong Shi, Jing Shi, Guangming Liu, Jianmin Wang, Huilin Zhao, Hongping Guo, Hongting Liu, Xiaofeng Wu, Liming Liu, Xiaohui Song, Jiangtao Zhu, Yawei Zhang, Yongliang Feng, Xiaofeng Liang, Suping Wang
Vaccine. 2021; 39(18): 2537
[Pubmed] | [DOI]
36 Ultrasound-visualized, site-specific vascular embolization using magnetic protein microcapsules
Lanxi Chen, Jianhua Zhou, Qiurong Deng, Jialin Feng, Qiong Qiu, Wenwei Huang, Yin Chen, Yan Li
Journal of Materials Chemistry B. 2021; 9(10): 2407
[Pubmed] | [DOI]
37 Molecular docking and dynamic simulations of Ocimum basilicum compounds against HCC and structural, vibrational, quantum, and chemical investigation of campesterol
R. Sangeetha, E. Arockia Jeya Yasmi Prabha, A. Lakshmi, P. Sangavi, K. Langeswaran
Journal of Biomolecular Structure and Dynamics. 2021; : 1
[Pubmed] | [DOI]
38 Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa
Ming-Lun Yeh, Jee-Fu Huang, Ming-Lung Yu, Wan-Long Chuang
Expert Review of Gastroenterology & Hepatology. 2021; 15(4): 427
[Pubmed] | [DOI]
39 Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis
Junjiang Fu, Li Liao, Kyathegowdanadoddi Srinivasa Balaji, Chunli Wei, Jaehoon Kim, Jiangzhou Peng
Oncogene. 2021; 40(3): 465
[Pubmed] | [DOI]
40 Hepatic Resection for Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease
Michele Molinari, Christof Kaltenmeier, Patrick-Bou Samra, Hao Liu, Charles Wessel, Mary Lou Klem, Stalin Dharmayan, Bishoy Emmanuel, Hasan Al Harakeh, Samer Tohme, David Geller, Amit Tevar, Christopher B. Hughes, Abhinav Humar, Ramon Bataller, Jaideep Behari
Annals of Surgery Open. 2021; 2(2): e065
[Pubmed] | [DOI]
41 Effectiveness of combined therapy radiofrequency ablation/transarterial chemoembolization versus transarterial chemoembolization/radiofrequency ablation on management of hepatocellular carcinoma
Ahmed Kaml El dorry, Mohammed Kamal Shaker, Nevien Fouad EL-Fouly, Ahmed Hussien, Runia Fouad El-Folly, Amr Hafez El Fouly, Karim Abd El Tawab
European Journal of Gastroenterology & Hepatology. 2021; 33(12): 1573
[Pubmed] | [DOI]
42 Hepatoid Teratoma, Hepatoid Yolk Sac Tumor, and Hepatocellular Carcinoma
Khaleel I. Al-Obaidy, Sean R. Williamson, Nathan Shelman, Muhammad T. Idrees, Thomas M. Ulbright
American Journal of Surgical Pathology. 2021; 45(1): 127
[Pubmed] | [DOI]
43 Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naďve patients with chronic hepatitis B following entecavir therapy
Joonho Jeong, Jung Woo Shin, Seok Won Jung, Seung Bum Lee, Eun Ji Park, Neung Hwa Park
Hepatology Research. 2021; 51(9): 923
[Pubmed] | [DOI]
44 Exosome circCMTM3 promotes angiogenesis and tumorigenesis of hepatocellular carcinoma through miR-3619-5p/SOX9
Ke Hu, Nian-Feng Li, Jia-Rong Li, Ze-Guo Chen, Jian-Hua Wang, Lang-Qing Sheng
Hepatology Research. 2021; 51(11): 1139
[Pubmed] | [DOI]
45 Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study
Margherita Rimini, Shigeo Shimose, Sara Lonardi, Toshifumi Tada, Gianluca Masi, Hideki Iwamoto, Eleonora Lai, Valentina Burgio, Atsushi Hiraoka, Toru Ishikawa, Caterina Soldŕ, Tomotake Shirono, Caterina Vivaldi, Koichi Takaguchi, Noritomo Shimada, Giorgio Astara, Hironori Koga, Kazuhiro Nouso, Kouji Joko, Takuji Torimura, Yoichi Hiasa, Francesca Salani, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Hepatology Research. 2021;
[Pubmed] | [DOI]
46 P53 suppresses the progression of hepatocellular carcinoma via miR-15a by decreasing OGT expression and EZH2 stabilization
Zhenyu You, Dandan Peng, Yixin Cao, Yuanzhe Zhu, Jianjun Yin, Guangxing Zhang, Xiaodong Peng
Journal of Cellular and Molecular Medicine. 2021; 25(19): 9168
[Pubmed] | [DOI]
47 Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma
Xiao-Han Cui, Qiu-Ju Peng, Ren-Zhi Li, Xia-Jie Lyu, Chun-Fu Zhu, Xi-Hu Qin
Journal of Cellular and Molecular Medicine. 2021;
[Pubmed] | [DOI]
48 Optimal Timing of Administration of Direct-Acting Antivirals for Patients with Hepatitis C-Associated Hepatocellular Carcinoma Undergoing Liver Transplantation
Michael K. Turgeon, Shimul A. Shah, Aaron M. Delman, Benjamin V. Tran, Vatche G. Agopian, Joel P. Wedd, Joseph F. Magliocca, Ahyoung Kim, Andrew Cameron, Ali Olyaei, Susan L. Orloff, Matthew P. Anderson, Chandrashekhar A. Kubal, Robert M. Cannon, Jayme E. Locke, Mary A. Simpson, Mohamed E. Akoad, Chelsey P. Wongjirad, Juliet Emamaullee, Amika Moro, Federico Aucejo, Cyrus A. Feizpour, Parsia A. Vagefi, Mindie H. Nguyen, Carlos O. Esquivel, Kiran Dhanireddy, Vijay Subramanian, Alejandro Chavarriaga, Marwan M. Kazimi, Maia S. Anderson, Christopher J. Sonnenday, Steven C. Kim, David P. Foley, Marwan Abdouljoud, Reena J. Salgia, Dimitrios Moris, Debra L. Sudan, Swaytha R. Ganesh, Abhinav Humar, Majella Doyle, William C. Chapman, Shishir K. Maithel
Annals of Surgery. 2021; Publish Ah
[Pubmed] | [DOI]
49 Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology
Peter R. Galle, Masatoshi Kudo, Josep M. Llovet, Richard S. Finn, Mark Karwal, Denis Pezet, Tae-You Kim, Tsai-Sheng Yang, Sara Lonardi, Jiri Tomasek, Jean-Marc Phelip, Yann Touchefeu, Su-Jin Koh, Guido Stirnimann, Kun Liang, Kenyon D. Ogburn, Chunxiao Wang, Paolo Abada, Ryan C. Widau, Andrew X. Zhu
Liver International. 2021; 41(11): 2759
[Pubmed] | [DOI]
50 E2F1-Induced lncRNA BAIAP2-AS1 Overexpression Contributes to the Malignant Progression of Hepatocellular Carcinoma via miR-361-3p/SOX4 Axis
Yan Yang, Hong Ge, De-qing Li, Ai-xia Xu, Fu Wang
Disease Markers. 2021; 2021: 1
[Pubmed] | [DOI]
51 Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma
Yuan Chen, Guifu Wang, Hao Xu, Hao Wang, Dousheng Bai, Raffaele Palmirotta
Journal of Oncology. 2021; 2021: 1
[Pubmed] | [DOI]
52 Unconventional Secretion of PKCd Exerts Tumorigenic Function via Stimulation of ERK1/2 Signaling in Liver Cancer
Kohji Yamada, Tsunekazu Oikawa, Ryusuke Kizawa, Saya Motohashi, Saishu Yoshida, Tomotaka Kumamoto, Chisato Saeki, Chika Nakagawa, Yuya Shimoyama, Katsuhiko Aoki, Toshiaki Tachibana, Masayuki Saruta, Masaya Ono, Kiyotsugu Yoshida
Cancer Research. 2021; 81(2): 414
[Pubmed] | [DOI]
53 Disparities in Hepatocellular Carcinoma Incidence, Stage, and Survival: A Large Population-Based Study
Yvonne N. Flores, Geetanjali D. Datta, Liu Yang, Edgar Corona, Divya Devineni, Beth A. Glenn, Roshan Bastani, Folasade P. May
Cancer Epidemiology Biomarkers & Prevention. 2021; 30(6): 1193
[Pubmed] | [DOI]
54 Computational intelligence identifies alkaline phosphatase (ALP), alpha-fetoprotein (AFP), and hemoglobin levels as most predictive survival factors for hepatocellular carcinoma
Davide Chicco, Luca Oneto
Health Informatics Journal. 2021; 27(1): 1460458220
[Pubmed] | [DOI]
55 Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (Hepatocellular carcinoma)
Alice R. Owens, Caitríona E. McInerney, Kevin M. Prise, Darragh G. McArt, Anna Jurek-Loughrey
BMC Bioinformatics. 2021; 22(1)
[Pubmed] | [DOI]
56 Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
Hui Li, Yujuan Liu, Wei Jiang, Junhui Xue, Yuning Cheng, Jiyin Wang, Ruixiang Yang, Xiaowei Zhang
BMC Cancer. 2021; 21(1)
[Pubmed] | [DOI]
57 MKL1 regulates hepatocellular carcinoma cell proliferation, migration and apoptosis via the COMPASS complex and NF-?B signaling
Zhao Liu, Jiuzheng Sun, Chuanzhi Li, Liyou Xu, Jun Liu
BMC Cancer. 2021; 21(1)
[Pubmed] | [DOI]
58 Hepatocyte ploidy in cats with and without hepatocellular carcinoma
Jacqueline Post, Ingeborg M. Langohr, Cynthia R.L. Webster, Peter Mottram, Chin-Chi Liu, Andrea Johnston
BMC Veterinary Research. 2021; 17(1)
[Pubmed] | [DOI]
59 Leptin Receptor (LEPR) promotes proliferation, migration, and invasion and inhibits apoptosis in hepatocellular carcinoma by regulating ANXA7
He Huang, Jun Zhang, Fei Ling, Yuhong Huang, Min Yang, Yao Zhang, Yuanyi Wei, Qingqing Zhang, Honghai Wang, Lin Song, Ying Wu, Jiayu Yang, Jianwu Tang
Cancer Cell International. 2021; 21(1)
[Pubmed] | [DOI]
60 A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma
Zaoqu Liu, Yuyuan Zhang, Chengcheng Shi, Xueliang Zhou, Kaihao Xu, Dechao Jiao, Zhenqiang Sun, Xinwei Han
Journal of Translational Medicine. 2021; 19(1)
[Pubmed] | [DOI]
61 Hepatitis B virus induces sorafenib resistance in liver cancer via upregulation of cIAP2 expression
Shouhua Zhang, Nuoya Li, Yanling Sheng, Wen Chen, Qiangliang Ma, Xin Yu, Jianping Lian, Junquan Zeng, Yipeng Yang, Jinlong Yan
Infectious Agents and Cancer. 2021; 16(1)
[Pubmed] | [DOI]
62 Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang
Biomarker Research. 2021; 9(1)
[Pubmed] | [DOI]
63 Signalling pathways and transcriptional regulators orchestrating liver development and cancer
Stephanie A. Campbell, Tabea L. Stephan, Jeremy Lotto, Rebecca Cullum, Sibyl Drissler, Pamela A. Hoodless
Development. 2021; 148(17)
[Pubmed] | [DOI]
64 Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study
Joshua P. Kronenfeld, Emily L. Ryon, David Goldberg, Rachel M. Lee, Adam Yopp, Annie Wang, Ann Y. Lee, Sommer Luu, Cary Hsu, Eric Silberfein, Maria C. Russell, Alan S. Livingstone, Nipun B. Merchant, Neha Goel
Annals of Surgical Oncology. 2021; 28(4): 1929
[Pubmed] | [DOI]
65 Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer
Matthew R. Woeste, Anne E. Geller, Robert C. G. Martin, Hiram C. Polk
Annals of Surgical Oncology. 2021; 28(3): 1499
[Pubmed] | [DOI]
66 Clinical application of mask region-based convolutional neural network for the automatic detection and segmentation of abnormal liver density based on hepatocellular carcinoma computed tomography datasets
Ching-Juei Yang, Chien-Kuo Wang, Yu-Hua Dean Fang, Jing-Yao Wang, Fong-Chin Su, Hong-Ming Tsai, Yih-Jyh Lin, Hung-Wen Tsai, Lee-Ren Yeh, Khanh N.Q. Le
PLOS ONE. 2021; 16(8): e0255605
[Pubmed] | [DOI]
67 Circ_0091579 enhances the malignancy of hepatocellular carcinoma via miR-1287/PDK2 axis
Junwei Shu, Jiayuan Du, Futao Wang, Yong Cheng, Gangxin Chen, Bing Xu, Dianpeng Zhang, Shuangjiang Chen
Open Life Sciences. 2021; 16(1): 69
[Pubmed] | [DOI]
68 Circular RNA circSP3 promotes hepatocellular carcinoma growth by sponging microRNA-198 and upregulating cyclin-dependent kinase 4
Molin Li, Hang Chen, Lulu Xia, Ping Huang
Aging. 2021; 13(14): 18586
[Pubmed] | [DOI]
69 Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy
Brian De, Sweet Ping Ng, Amy Y Liu, Santiago Avila, Randa Tao, Emma B Holliday, Zachary Brownlee, Ahmed Kaseb, Sunyoung Lee, Kanwal Raghav, Jean-Nicolas Vauthey, Bruce D Minsky, Joseph M Herman, Prajnan Das, Grace Smith, Cullen Taniguchi, Sunil Krishnan, Christopher H Crane, Clemens Grassberger, Theodore Hong, Steven H Lin, Albert C Koong, Radhe Mohan, Eugene J Koay
Journal of Hepatocellular Carcinoma. 2021; Volume 8: 57
[Pubmed] | [DOI]
70 Molecular Signature and Immune Landscape of HCV-Associated Hepatocellular Carcinoma (HCC): Differences and Similarities with HBV-HCC
Davide De Battista, Fausto Zamboni, Hannah Gerstein, Shinya Sato, Tovah E Markowitz, Justin Lack, Ronald E Engle, Patrizia Farci
Journal of Hepatocellular Carcinoma. 2021; Volume 8: 1399
[Pubmed] | [DOI]
71 Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features
Anastasia Murtha-Lemekhova, Juri Fuchs, Erik Schulz, Anthe Suzan Sterkenburg, Philipp Mayer, Jan Pfeiffenberger, Katrin Hoffmann
Journal of Hepatocellular Carcinoma. 2021; Volume 8: 1269
[Pubmed] | [DOI]
72 Vitamin D Receptor Gene Polymorphisms and the Risk of Chronic Hepatitis C Related Hepatocellular Carcinoma in Egyptian Population
Amal A. Mohamed, Sherief Abd-Elsalam, Hanan M. Mostafa, Asmaa Abdalla, Ahmed Farouk, Ahmed M. Aref, Reham A.A. Elshmiy, Eman ElSayed, Nevine F. Shafik, Maha O. Mahmoud, Moustafa Al-Daly, Mariam S. Zaghloul
The Open Biomarkers Journal. 2021; 11(1): 79
[Pubmed] | [DOI]
73 Comparison of Conventional Gadoxetate Disodium–Enhanced MRI Features and Radiomics Signatures With Machine Learning for Diagnosing Microvascular Invasion
Yidi Chen, Yuwei Xia, Parag P. Tolat, Liling Long, Zijian Jiang, Zhongkui Huang, Qin Tang
American Journal of Roentgenology. 2021; 216(6): 1510
[Pubmed] | [DOI]
74 Current State and Progress of Research on the Role of lncRNA in HBV-Related Liver Cancer
Xueke Wang, Meisong Kang, Chun Liu, Ting Lin, Xiao Han, Xiwen Jiang
Frontiers in Cellular and Infection Microbiology. 2021; 11
[Pubmed] | [DOI]
75 The Potential of Serum Exosomal hsa_circ_0028861 as the Novel Diagnostic Biomarker of HBV-Derived Hepatocellular Cancer
Yuanxiao Wang, Lin Pei, Zhihong Yue, Mei Jia, Hui Wang, Lin-Lin Cao
Frontiers in Genetics. 2021; 12
[Pubmed] | [DOI]
76 The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma
Soudeh Ghafouri-Fard, Mahdi Gholipour, Bashdar Mahmud Hussen, Mohammad Taheri
Frontiers in Oncology. 2021; 11
[Pubmed] | [DOI]
77 Loss of Tid1/DNAJA3 Co-Chaperone Promotes Progression and Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Novel Model to Stratify Risk of Recurrence
Kuan-Yang Chen, Yi-Hsiang Huang, Wan-Huai Teo, Ching-Wen Chang, Yu-Syuan Chen, Yi-Chen Yeh, Chieh-Ju Lee, Jeng-Fan Lo
Cancers. 2021; 13(1): 138
[Pubmed] | [DOI]
78 Serum Response Factor (SRF) Drives the Transcriptional Upregulation of the MDM4 Oncogene in HCC
Rossella Pellegrino, Abhishek Thavamani, Diego F. Calvisi, Jan Budczies, Ariane Neumann, Robert Geffers, Jasmin Kroemer, Damaris Greule, Peter Schirmacher, Alfred Nordheim, Thomas Longerich
Cancers. 2021; 13(2): 199
[Pubmed] | [DOI]
79 Shorter Survival after Liver Pedicle Clamping in Patients Undergoing Liver Resection for Hepatocellular Carcinoma Revealed by a Systematic Review and Meta-Analysis
Charles-Henri Wassmer, Beat Moeckli, Thierry Berney, Christian Toso, Lorenzo A. Orci
Cancers. 2021; 13(4): 637
[Pubmed] | [DOI]
80 Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy
Konstantinos Arvanitakis, Ioannis Mitroulis, Georgios Germanidis
Cancers. 2021; 13(12): 2899
[Pubmed] | [DOI]
81 Experimental Models of Hepatocellular Carcinoma—A Preclinical Perspective
Alexandru Blidisel, Iasmina Marcovici, Dorina Coricovac, Florin Hut, Cristina Adriana Dehelean, Octavian Marius Cretu
Cancers. 2021; 13(15): 3651
[Pubmed] | [DOI]
82 Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma
Melissa Borgia, Michele Dal Bo, Giuseppe Toffoli
Cancers. 2021; 13(17): 4387
[Pubmed] | [DOI]
83 Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer
Po-Shuan Huang, Chia-Jung Liao, Ya-Hui Huang, Chau-Ting Yeh, Cheng-Yi Chen, Hui-Chi Tang, Cheng-Chih Chang, Kwang-Huei Lin
Cancers. 2021; 13(21): 5361
[Pubmed] | [DOI]
84 Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway
Loukik Arora, Chakrabhavi Dhananjaya Mohan, Min Hee Yang, Shobith Rangappa, Amudha Deivasigamani, Alan Prem Kumar, Ajaikumar B. Kunnumakkara, Manoj Garg, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, Tahani Awad Alahmadi, Kanchugarakoppal S. Rangappa, Kam Man Hui, Gautam Sethi, Kwang Seok Ahn
Cancers. 2021; 13(21): 5479
[Pubmed] | [DOI]
85 Chemotherapy-Induced Hepatotoxicity in HIV Patients
Silvia Bressan, Alessandra Pierantoni, Saman Sharifi, Sergio Facchini, Vincenzo Quagliarello, Massimiliano Berretta, Monica Montopoli
Cells. 2021; 10(11): 2871
[Pubmed] | [DOI]
86 The Gut–Liver Axis in Chronic Liver Disease: A Macrophage Perspective
Kevin De Muynck, Bart Vanderborght, Hans Van Vlierberghe, Lindsey Devisscher
Cells. 2021; 10(11): 2959
[Pubmed] | [DOI]
87 Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis
Dong Wook Kim, Sang Hyun Choi, Ji Sung Lee, So Yeon Kim, So Jung Lee, Jae Ho Byun
Diagnostics. 2021; 11(2): 237
[Pubmed] | [DOI]
88 Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC
Hyo Jung Cho, Geum Ok Baek, Moon Gyeong Yoon, Hye Ri Ahn, Ju A Son, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
Diagnostics. 2021; 11(7): 1221
[Pubmed] | [DOI]
89 A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients
Luca Bedon, Michele Dal Bo, Monica Mossenta, Davide Busato, Giuseppe Toffoli, Maurizio Polano
International Journal of Molecular Sciences. 2021; 22(3): 1075
[Pubmed] | [DOI]
90 Mechanisms by Which Probiotic Bacteria Attenuate the Risk of Hepatocellular Carcinoma
Wasitha P.D. Wass Thilakarathna, H.P. Vasantha Rupasinghe, Neale D. Ridgway
International Journal of Molecular Sciences. 2021; 22(5): 2606
[Pubmed] | [DOI]
91 Moscatilin Inhibits Metastatic Behavior of Human Hepatocellular Carcinoma Cells: A Crucial Role of uPA Suppression via Akt/NF-?B-Dependent Pathway
Chen-Lin Yu, Meng-Shih Weng, Wei-Cheng Chen, Kai-Ting Chien, Chih-Wen Chi, Ching-Hu Chung, Chia-Wen Huang, Po-Chuan Wang, Chien-Chih Chen, An-Chi Tsai, Shih-Chia Liu, Shih-Wei Wang
International Journal of Molecular Sciences. 2021; 22(6): 2930
[Pubmed] | [DOI]
92 Genome-Wide Methylation Mapping Using Nanopore Sequencing Technology Identifies Novel Tumor Suppressor Genes in Hepatocellular Carcinoma
Colin F. Davenport, Tobias Scheithauer, Alessia Dunst, Frauke Sophie Bahr, Marie Dorda, Lutz Wiehlmann, Doan Duy Hai Tran
International Journal of Molecular Sciences. 2021; 22(8): 3937
[Pubmed] | [DOI]
93 Visualizing Extracellular Vesicles and Their Function in 3D Tumor Microenvironment Models
Evran E. Ural, Victoria Toomajian, Ehsanul Hoque Apu, Mladen Veletic, Ilangko Balasingham, Nureddin Ashammakhi, Masamitsu Kanada, Christopher H. Contag
International Journal of Molecular Sciences. 2021; 22(9): 4784
[Pubmed] | [DOI]
94 Graphene Oxide Loaded with Protocatechuic Acid and Chlorogenic Acid Dual Drug Nanodelivery System for Human Hepatocellular Carcinoma Therapeutic Application
Kalaivani Buskaran, Mohd Zobir Hussein, Mohamad Aris Mohd Moklas, Mas Jaffri Masarudin, Sharida Fakurazi
International Journal of Molecular Sciences. 2021; 22(11): 5786
[Pubmed] | [DOI]
95 Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma
Younglan Lim, Nam-On Ku
International Journal of Molecular Sciences. 2021; 22(12): 6401
[Pubmed] | [DOI]
96 Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Anne Dyhl-Polk, Marta Kramer Mikkelsen, Morten Ladekarl, Dorte Lisbet Nielsen
Journal of Clinical Medicine. 2021; 10(12): 2662
[Pubmed] | [DOI]
97 Intermediate Stage Hepatocellular Carcinoma Classifications: the Review
D. M. Khaitsman, I. V. Pogrebnyakov, E. R. Virshke, I. A. Trofimov, D. Yu. Frantsev, I. A. Dzhanyan, V. V. Breder, B. I. Dolgushin
Journal of oncology: diagnostic radiology and radiotherapy. 2021; 4(1): 53
[Pubmed] | [DOI]
98 Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma
Guang-Lin Lei, Hong-Xia Fan, Cheng Wang, Yan Niu, Tie-Ling Li, Ling-Xiang Yu, Zhi-Xian Hong, Jin Yan, Xi-Liang Wang, Shao-Geng Zhang, Ming-Ji Ren, Peng-Hui Yang
World Journal of Gastroenterology. 2021; 27(1): 55
[Pubmed] | [DOI]
99 Cyanidin 3-glucoside modulated cell cycle progression in liver precancerous lesion, in vivo study
Marwa Matboli, Amany H Hasanin, Reham Hussein, Sarah El-Nakeep, Eman K Habib, Rawan Ellackany, Lobna A Saleh
World Journal of Gastroenterology. 2021; 27(14): 1435
[Pubmed] | [DOI]
100 The Association between Diet and Hepatocellular Carcinoma: A Systematic Review
Elena S. George, Surbhi Sood, Anna Broughton, Georgia Cogan, Megan Hickey, Wai San Chan, Sonal Sudan, Amanda J. Nicoll
Nutrients. 2021; 13(1): 172
[Pubmed] | [DOI]
101 The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review
Francesca Matilde Schipilliti, Ingrid Garajová, Giulia Rovesti, Rita Balsano, Federico Piacentini, Massimo Dominici, Fabio Gelsomino
Pharmaceuticals. 2021; 14(1): 43
[Pubmed] | [DOI]
102 Hepatocellular-Targeted mRNA Delivery Using Functionalized Selenium Nanoparticles In Vitro
Dhireshan Singh, Moganavelli Singh
Pharmaceutics. 2021; 13(3): 298
[Pubmed] | [DOI]
103 Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18ß-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer
Luciano A. Stecanella, Antonio P. R. Bitencourt, Gustavo Richter Vaz, Eride Quarta, José O. C. Silva Júnior, Alessandra Rossi
Pharmaceutics. 2021; 13(11): 1792
[Pubmed] | [DOI]
104 Immunotoxins Immunotherapy against Hepatocellular Carcinoma: A Promising Prospect
Mohammad Heiat, Hamid Hashemi Yeganeh, Seyed Moayed Alavian, Ehsan Rezaie
Toxins. 2021; 13(10): 719
[Pubmed] | [DOI]
105 Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study
Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park
Clinical and Molecular Hepatology. 2021; 27(1): 144
[Pubmed] | [DOI]
106 Analysis of Results of Liver-related Health Care Checkup in Mongolian Immigrants: A Comparison with Results from Koreans
Duk Hyun Kim, Jin Kyung Lee, Heyjin Kim, Ae-chin Oh, Young Jun Hong, Su Cheol Park, Chang-Bae Kong
Laboratory Medicine Online. 2021; 11(2): 88
[Pubmed] | [DOI]
107 Analysis of the Current Status of Liver Cancer Screening Institutions and Proficiency of Institutions that Conduct Alpha-fetoprotein Tests
Jong Kwon Lee, Taek Soo Kim, Junghan Song, Woo-In Lee, Dahun Jang, Yeol Kim, Mina Suh, Sail Chun, Hyung-Doo Park
Laboratory Medicine Online. 2021; 11(4): 245
[Pubmed] | [DOI]
108 Post-Embolization Syndrome Complicated by Hypertensive Emergency and Severely Elevated Transaminases
Simon Kashfi, Elizabeth Murdakhayev , Razia Rehmani, Shorabh Sharma
Cureus. 2021;
[Pubmed] | [DOI]
109 Clinical and laboratory parameters as predictors of long-term outcome according to the etiology of underlying chronic liver disease in patients who underwent liver transplantation for hepatocellular carcinoma treatment
Paulo Henrique Costa Diniz, Serena Dafne do Carmo Silva, Luciana Costa Faria, Paula Vieira Teixeira Vidigal, Teresa Cristina de Abreu Ferrari
Clinics. 2020; 75
[Pubmed] | [DOI]
110 Autophagy-related genes prognosis signature as potential predictive markers for immunotherapy in hepatocellular carcinoma
Deli Mao, Zhe Zhang, Xin Zhao, Xiaoqiang Dong
PeerJ. 2020; 8: e8383
[Pubmed] | [DOI]
111 Increased Expression of Fibulin-1 Is Associated With Hepatocellular Carcinoma Progression by Regulating the Notch Signaling Pathway
Jiao Gong, Yusheng Jie, Cuicui Xiao, Wenying Zhou, Xinhua Li, Yaqiong Chen, Yuankai Wu, Jing Cao, Qi Zhang, Zhiliang Gao, Bo Hu, Yutian Chong
Frontiers in Cell and Developmental Biology. 2020; 8
[Pubmed] | [DOI]
112 Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation
Kumar Jayant, Nagy Habib, Kai W. Huang, Mauro Podda, Jane Warwick, Ramesh Arasaradnam
Vaccines. 2020; 8(2): 247
[Pubmed] | [DOI]
113 Bioactive Compounds of Seaweeds and Their Effects on Certain Types of Cancer
Omniya M. Abd-Elazeem, Nehal A.H.k. Osman, Nahla S. El-Shenawy
Avicenna Journal of Medical Biochemistry. 2020; 8(2): 112
[Pubmed] | [DOI]
114 Bioinformatics analysis reveals meaningful markers and outcome predictors in HBV-associated hepatocellular carcinoma
Lijie Zhang, Joyman Makamure, Dan Zhao, Yiming Liu, Xiaopeng Guo, Chuansheng Zheng, Bin Liang
Experimental and Therapeutic Medicine. 2020; 20(1): 427
[Pubmed] | [DOI]
115 Sevoflurane inhibits the proliferation and invasion of hepatocellular carcinoma cells through regulating the PTEN/Akt/GSK-3ß/ß-catenin signaling pathway by downregulating miR-25-3p
Yinghao Cao, Wenfei Lv, Wan Ding, Jun Li
International Journal of Molecular Medicine. 2020;
[Pubmed] | [DOI]
116 Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma
Hyo Cho, Jung Eun, Geum Baek, Chul Seo, Hye Ahn, Soon Kim, Sung Cho, Jae Cheong
Journal of Clinical Medicine. 2020; 9(1): 281
[Pubmed] | [DOI]
117 Combined Liver and Inferior Vena Cava Resection for Malignancies Is Safe and Feasible in a Group of High-Risk Patients
Sandra Schipper, Markus Zimmermann, Andreas Kroh, Ulf Peter Neumann, Tom Florian Ulmer
Journal of Clinical Medicine. 2020; 9(4): 1100
[Pubmed] | [DOI]
118 Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
Bryan Mckiver, Mohamad Imad Damaj, Devanand Sarkar
Gastrointestinal Disorders. 2020; 2(4): 469
[Pubmed] | [DOI]
119 Liver Cancer Incidence and Area-Level Geographic Disparities in Pennsylvania—A Geo-Additive Approach
Angel G. Ortiz, Daniel Wiese, Kristen A. Sorice, Minhhuyen Nguyen, Evelyn T. González, Kevin A. Henry, Shannon M. Lynch
International Journal of Environmental Research and Public Health. 2020; 17(20): 7526
[Pubmed] | [DOI]
120 Claudin-1, A Double-Edged Sword in Cancer
Ajaz A. Bhat, Najeeb Syed, Lubna Therachiyil, Sabah Nisar, Sheema Hashem, Muzafar A. Macha, Santosh K. Yadav, Roopesh Krishnankutty, Shanmugakonar Muralitharan, Hamda Al-Naemi, Puneet Bagga, Ravinder Reddy, Punita Dhawan, Anthony Akobeng, Shahab Uddin, Michael P. Frenneaux, Wael El-Rifai, Mohammad Haris
International Journal of Molecular Sciences. 2020; 21(2): 569
[Pubmed] | [DOI]
121 The CCL20-CCR6 Axis in Cancer Progression
Suguru Kadomoto, Kouji Izumi, Atsushi Mizokami
International Journal of Molecular Sciences. 2020; 21(15): 5186
[Pubmed] | [DOI]
122 Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review
Yi-Hsun Chen, Wei-Kai Wu, Ming-Shiang Wu
International Journal of Molecular Sciences. 2020; 21(17): 5999
[Pubmed] | [DOI]
123 Ligation-Mediated Polymerase Chain Reaction Detection of 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine and 5-Hydroxycytosine at the Codon 176 of the p53 Gene of Hepatitis C-Associated Hepatocellular Carcinoma Patients
Andrea Galli, Armelle Munnia, Filippo Cellai, Mirko Tarocchi, Elisabetta Ceni, Frederik Jan van Schooten, Roger Godschalk, Roger W. Giese, Marco Peluso
International Journal of Molecular Sciences. 2020; 21(18): 6753
[Pubmed] | [DOI]
124 The Non-Coding RNA GAS5 and Its Role in Tumor Therapy-Induced Resistance
George I. Lambrou, Kyriaki Hatziagapiou, Apostolos Zaravinos
International Journal of Molecular Sciences. 2020; 21(20): 7633
[Pubmed] | [DOI]
125 The Angiopoietin/Tie2 Pathway in Hepatocellular Carcinoma
Bart Vanderborght, Sander Lefere, Hans Van Vlierberghe, Lindsey Devisscher
Cells. 2020; 9(11): 2382
[Pubmed] | [DOI]
126 Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma
Kumar Jayant, Nagy Habib, Kai W. Huang, Jane Warwick, Ramesh Arasaradnam
Diagnostics. 2020; 10(5): 338
[Pubmed] | [DOI]
127 Diagnostic Value of CEUS Prompting Liver Biopsy: Histopathological Correlation of Hepatic Lesions with Ambiguous Imaging Characteristics
Thomas Geyer, Dirk-André Clevert, Sonja Schwarz, Paul Reidler, Sebastian Gassenmaier, Thomas Knösel, Johannes Rübenthaler, Vincent Schwarze, Marco Armbruster
Diagnostics. 2020; 11(1): 35
[Pubmed] | [DOI]
128 Chinese Dragon’s Blood EtOAc Extract Inhibits Liver Cancer Growth Through Downregulation of Smad3
Xiaonan Chen, Yanan Zhao, Ailin Yang, Yingying Tian, Daoran Pang, Jing Sun, Leimengyuan Tang, Huiming Huang, Ying Wang, Yunfang Zhao, Pengfei Tu, Zhongdong Hu, Jun Li
Frontiers in Pharmacology. 2020; 11
[Pubmed] | [DOI]
129 Antiproliferative Activity of Pyracantha and Paullinia Plant Extracts on Aggressive Breast and Hepatocellular Carcinoma Cells
Neha Kaushik, Hyeonyeong Yang, SungRyong Jeong, Nagendra Kumar Kaushik, Pradeep Bhartiya, Linh Nhat Nguyen, Eun Ha Choi, June Hyun Kim
Applied Sciences. 2020; 10(21): 7543
[Pubmed] | [DOI]
130 Statin Use and the Risk of Hepatocellular Carcinoma: A Meta-Analysis of Observational Studies
Md. Mohaimenul Islam, Tahmina Nasrin Poly, Bruno Andreas Walther, Hsuan-Chia Yang, Yu-Chuan (Jack) Li
Cancers. 2020; 12(3): 671
[Pubmed] | [DOI]
131 Transitions of Liver and Biliary Enzymes during Proton Beam Therapy for Hepatocellular Carcinoma
Taisuke Sumiya, Masashi Mizumoto, Yoshiko Oshiro, Keiichiro Baba, Motohiro Murakami, Shosei Shimizu, Masatoshi Nakamura, Yuichi Hiroshima, Toshiki Ishida, Takashi Iizumi, Takashi Saito, Haruko Numajiri, Kei Nakai, Toshiyuki Okumura, Hideyuki Sakurai
Cancers. 2020; 12(7): 1840
[Pubmed] | [DOI]
132 Circulating Exosomal MicroRNA-1307-5p as a Predictor for Metastasis in Patients with Hepatocellular Carcinoma
Jung Woo Eun, Chul Won Seo, Geum Ok Baek, Moon Gyeong Yoon, Hye Ri Ahn, Ju A. Son, Suna Sung, Do Wan Kim, Soon Sun Kim, Hyo Jung Cho, Jae Youn Cheong
Cancers. 2020; 12(12): 3819
[Pubmed] | [DOI]
133 Optimization of In vivo Imaging Provides a First Look at Mouse Model of Non-Alcoholic Fatty Liver Disease (NAFLD) Using Intravital Microscopy
Rachelle P. Davis, Bas G. J. Surewaard, Madison Turk, Agostina Carestia, Woo-Yong Lee, Björn Petri, Stefan J. Urbanski, Carla S. Coffin, Craig N. Jenne
Frontiers in Immunology. 2020; 10
[Pubmed] | [DOI]
134 Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
Yun Hua Lee, David Tai, Connie Yip, Su Pin Choo, Valerie Chew
Frontiers in Immunology. 2020; 11
[Pubmed] | [DOI]
135 Heat Shock Protein 60 in Hepatocellular Carcinoma: Insights and Perspectives
Abdullah Hoter, Sandra Rizk, Hassan Y. Naim
Frontiers in Molecular Biosciences. 2020; 7
[Pubmed] | [DOI]
136 Update on the Genetics of and Systemic Therapy Options for Combined Hepatocellular Cholangiocarcinoma
Alexander A. Azizi, Andreas V. Hadjinicolaou, Carla Goncalves, Adam Duckworth, Bristi Basu
Frontiers in Oncology. 2020; 10
[Pubmed] | [DOI]
137 The effect of capsaicin and diethylnitrosamine on mouse nephrotoxicity, hepatotoxicity and hepatocarcinogenesis
Vendula Kucharová Kumžáková, Ivana Veselá, Miša Škoric, Ondrej Danek, Kristína Reháková, Jaroslava Tomenendálová
Acta Veterinaria Brno. 2020; 89(4): 383
[Pubmed] | [DOI]
138 Identification and Differential Expression of microRNA in Response to Elevated Phospholipase C? Expression in Liver RH 35 Carcinoma Cells
Xiaoguang Chen, Xuemin Zhu, Zhiguo Wei, Qiongxia Lv
Cytology and Genetics. 2020; 54(6): 555
[Pubmed] | [DOI]
139 Evaluation of Cytotoxic Activity of Lavandula stoechas Aerial Parts Fractions against HepG2 Cell Lines
Mohd. A. Siddiqui , Hefazat H. Siddiqui, Anuradha Mishra , Afreen Usmani
Current Bioactive Compounds. 2020; 16(9): 1281
[Pubmed] | [DOI]
140 Evaluation of a Series of Lipidated Tucaresol Adjuvants in a Hepatitis C Virus Vaccine Model
Tyson F. Belz, Margaret E. Olson, Erick Giang, Mansun Law, Kim D. Janda
ACS Medicinal Chemistry Letters. 2020; 11(12): 2428
[Pubmed] | [DOI]
141 Effect of isoform-specific HIF-1a and HIF-2a antisense oligonucleotides on tumorigenesis, inflammation and fibrosis in a hepatocellular carcinoma mouse model
Bart Vanderborght, Kevin De Muynck, Sander Lefere, Anja Geerts, Helena Degroote, Xavier Verhelst, Hans Van Vlierberghe, Lindsey Devisscher
Oncotarget. 2020; 11(48): 4504
[Pubmed] | [DOI]
142 Pediatric hepatocellular carcinoma - the main differences from adult patients
D. G. Akhaladze, G. S. Rabaev
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2020; 25(4): 85
[Pubmed] | [DOI]
143 Liver Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance
So Hyun Park, Bohyun Kim
Journal of Liver Cancer. 2020; 20(1): 25
[Pubmed] | [DOI]
144 Gut-microbiome Taxonomic Profiling as Non-invasive Biomarkers for the Early Detection of Alcoholic Hepatocellular Carcinoma
Jun Seok, Ki Tae Suk
Journal of Liver Cancer. 2020; 20(1): 32
[Pubmed] | [DOI]
145 Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis
Georgia Zeng, Upkar S Gill, Patrick T F Kennedy
Gut. 2020; 69(11): 1907
[Pubmed] | [DOI]
146 Circulating levels of microRNA193a-5p predict outcome in early stage hepatocellular carcinoma
Sven H. Loosen, Theresa H. Wirtz, Sanchari Roy, Mihael Vucur, Mirco Castoldi, Anne T. Schneider, Christiane Koppe, Tom F. Ulmer, Anjali A. Roeth, Jan Bednarsch, Patrick H. Alizai, Pia Paffenholz, Münevver Demir, Christian Trautwein, Frank Tacke, Ulf P. Neumann, Christoph Roderburg, Tom Luedde, Matias A Avila
PLOS ONE. 2020; 15(9): e0239386
[Pubmed] | [DOI]
147 In vitro assessment of the cytotoxic effects of secondary metabolites from Spirulina platensis on hepatocellular carcinoma
Mahboobeh Akbarizare, Hamideh Ofoghi, Mahnaz Hadizadeh, Nasrin Moazami
Egyptian Liver Journal. 2020; 10(1)
[Pubmed] | [DOI]
148 Body mass index (BMI) and alpha-fetoprotein (AFP) level correlate with the severity of HCV-induced fibrosis in a cohort of Egyptian patients with chronic HCV
Amal Ahmed Mohamed, Amr Ali Hemeda, Ramy Karam Aziz, Mohamed Salaheldin Abdel-Hakeem, Marwa Ali-Tammam
Future Journal of Pharmaceutical Sciences. 2020; 6(1)
[Pubmed] | [DOI]
149 The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey
Moussa Lingani, Tomoyuki Akita, Serge Ouoba, Shintaro Nagashima, Palwende Romuald Boua, Kazuaki Takahashi, Basile Kam, Aya Sugiyama, Théodore Nikiema, Chikako Yamamoto, Athanase Somé, Karim Derra, Ko Ko, Hermann Sorgho, Zekiba Tarnagda, Halidou Tinto, Junko Tanaka
BMC Infectious Diseases. 2020; 20(1)
[Pubmed] | [DOI]
150 Silencing of microRNA-210 inhibits the progression of liver cancer and hepatitis B virus-associated liver cancer via targeting EGR3
Xiaojie Li, Mei Yuan, Lu Song, Yan Wang
BMC Medical Genetics. 2020; 21(1)
[Pubmed] | [DOI]
151 Genomic subtyping of liver cancers with prognostic application
Zhenggang Wu, Xi Long, Shui Ying Tsang, Taobo Hu, Jian-Feng Yang, Wai Kin Mat, Hongyang Wang, Hong Xue
BMC Cancer. 2020; 20(1)
[Pubmed] | [DOI]
152 Helical IMRT-Based Stereotactic Body Radiation Therapy Using an Abdominal Compression Technique and Modified Fractionation Regimen for Small Hepatocellular Carcinoma
Yi-Xing Chen, Yuan Zhuang, Ping Yang, Jia Fan, Jian Zhou, Yong Hu, Wen-Chao Zhu, Jing Sun, Zhao-Chong Zeng
Technology in Cancer Research & Treatment. 2020; 19: 1533033820
[Pubmed] | [DOI]
153 Circulating biomarkers for early detection of hepatocellular carcinoma
Boris J. B. Beudeker, Andre Boonstra
Therapeutic Advances in Gastroenterology. 2020; 13: 1756284820
[Pubmed] | [DOI]
154 GNAS promotes inflammation-related hepatocellular carcinoma progression by promoting STAT3 activation
Hongda Ding, Xixia Zhang, Yang Su, Changjun Jia, Chaoliu Dai
Cellular & Molecular Biology Letters. 2020; 25(1)
[Pubmed] | [DOI]
155 hsa_circ_0006916 promotes hepatocellular carcinoma progression by activating the miR-337-3p/STAT3 axis
Xiao-Yong Zhou, Hui Yang, Yang-Qiu Bai, Xiu-Ling Li, Shuang-Yin Han, Bing-Xi Zhou
Cellular & Molecular Biology Letters. 2020; 25(1)
[Pubmed] | [DOI]
156 Identification by TCGA database search of five genes that are aberrantly expressed and involved in hepatocellular carcinoma potentially via DNA methylation changes
Junya Matsushita, Takehiro Suzuki, Kazuyuki Okamura, Gaku Ichihara, Keiko Nohara
Environmental Health and Preventive Medicine. 2020; 25(1)
[Pubmed] | [DOI]
157 Effect of co-treatment with doxorubicin and verapamil loaded into chitosan nanoparticles on diethylnitrosamine-induced hepatocellular carcinoma in mice
HE Abo Mansour, MM El-Batsh, NS Badawy, ET Mehanna, NM Mesbah, DM Abo-Elmatty
Human & Experimental Toxicology. 2020; 39(11): 1528
[Pubmed] | [DOI]
158 Sociodemographic Characteristics as Predictors of Outcomes in Hepatocellular Carcinoma: A Retrospective Cohort Study
Bryce D. Beutler, Mark B. Ulanja, Rohee Krishan, Vijay Aluru, Munachismo L. Ndukwu, Molly M. Hagen, Zachary D. Dupin, Charles E. Willyard, Alastair E. Moody, Killian Boampong-Konam, Steven C. Zell
Cancer Control. 2020; 27(1): 1073274820
[Pubmed] | [DOI]
159 Weighted Gene Coexpression Network Analysis Reveals the Dynamic Transcriptome Regulation and Prognostic Biomarkers of Hepatocellular Carcinoma
Shuping Qu, Qiuyuan Shi, Jing Xu, Wanwan Yi, Hengwei Fan
Evolutionary Bioinformatics. 2020; 16: 1176934320
[Pubmed] | [DOI]
160 Hepatic volume changes post-selective internal radiation therapy with 90 Y microspheres
Frederick Ong, Jonathan Tibballs
Journal of Medical Imaging and Radiation Oncology. 2020; 64(3): 347
[Pubmed] | [DOI]
161 Modulation of Nqo1 activity intercepts anoikis resistance and reduces metastatic potential of hepatocellular carcinoma
Masahiro Shimokawa, Tomoharu Yoshizumi, Shinji Itoh, Norifumi Iseda, Kazuhito Sakata, Kyohei Yugawa, Takeo Toshima, Noboru Harada, Toru Ikegami, Masaki Mori
Cancer Science. 2020; 111(4): 1228
[Pubmed] | [DOI]
162 Black tea and curcumin synergistically mitigate the hepatotoxicity and nephropathic changes induced by chronic exposure to aflatoxin-B1 in Sprague–Dawley rats
Haitham I. El-Mekkawy, Mohammed A. Al-Kahtani, Ali A. Shati, Mohammed A. Alshehri, Amin A. Al-Doaiss, Ahmed A. Elmansi, Ahmed Ezzat Ahmed
Journal of Food Biochemistry. 2020; 44(9)
[Pubmed] | [DOI]
163 The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida
Paulo S. Pinheiro, Heidy N. Medina, Karen E. Callahan, Patricia D. Jones, Clyde P. Brown, Sean F. Altekruse, Katherine A. McGlynn, Erin N. Kobetz
Liver International. 2020; 40(5): 1201
[Pubmed] | [DOI]
164 Hypothermic Oxygenated Liver Perfusion (HOPE) Prevents Tumor Recurrence in Liver Transplantation From Donation After Circulatory Death
Matteo Mueller, Marit Kalisvaart, Joanne O‘Rourke, Shishir Shetty, Alessandro Parente, Xavier Muller, John Isaac, Beat Muellhaupt, Paolo Muiesan, Tahir Shah, Pierre-Alain Clavien, Andrea Schlegel, Philipp Dutkowski
Annals of Surgery. 2020; 272(5): 759
[Pubmed] | [DOI]
165 Among Medicare Patients With Hepatocellular Carcinoma, Non–alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality
Danubia Hester, Pegah Golabi, James Paik, Issah Younossi, Alita Mishra, Zobair M. Younossi
Journal of Clinical Gastroenterology. 2020; 54(5): 459
[Pubmed] | [DOI]
166 Cancer risk in road transportation workers: a national representative cohort study with 600,000 person-years of follow-up
Wanhyung Lee, Mo-Yeol Kang, Jihyun Kim, Sung-Shil Lim, Jin-Ha Yoon
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
167 Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma
Jiuwei Zhang, Yaodong Chen, Jing Lin, Ruimei Jia, Tingting An, Tianxiu Dong, Yu Zhang, Xiuhua Yang
DNA and Cell Biology. 2020; 39(3): 355
[Pubmed] | [DOI]
168 In SilicoIdentification of Crucial Genes and Specific Pathways in Hepatocellular Cancer
Yixin Sun, Zhiming Zhang
Genetic Testing and Molecular Biomarkers. 2020; 24(5): 296
[Pubmed] | [DOI]
169 Detection of Circulating Antibodies to p16 Protein-Derived Peptides in Hepatocellular Carcinoma
Yangchun Xu, Litong Gu, Jiaxin Wang, Zhenqi Wang, Ping Zhang, Xuan Zhang
Laboratory Medicine. 2020; 51(6): 574
[Pubmed] | [DOI]
170 Cabozantinib as a second-line treatment option in hepatocellular carcinoma
Alberto D’Angelo, Navid Sobhani, Stefan Bagby, Andrea Casadei-Gardini, Giandomenico Roviello
Expert Review of Clinical Pharmacology. 2020; 13(6): 623
[Pubmed] | [DOI]
171 Methylenetetrahydrofolate reductase C677T (Ala>Val, rs1801133 C>T) polymorphism decreases the susceptibility of hepatocellular carcinoma: a meta-analysis involving 12,628 subjects
Sheng Zhang, Jiakai Jiang, Weifeng Tang, Longgen Liu
Bioscience Reports. 2020; 40(2)
[Pubmed] | [DOI]
172 Ginger Extract Loaded into Chitosan Nanoparticles Enhances Cytotoxicity and Reduces Cardiotoxicity of Doxorubicin in Hepatocellular Carcinoma in Mice
Hend E. Abo Mansour, Maha M. El-Batsh, Nadia S. Badawy, Eman T. Mehanna, Noha M. Mesbah, Dina M. Abo-Elmatty
Nutrition and Cancer. 2020; : 1
[Pubmed] | [DOI]
173 Comparison between percutaneous and laparoscopic microwave ablation of hepatocellular carcinoma
Angelo Della Corte, Francesca Ratti, Lorenzo Monfardini, Paolo Marra, Simone Gusmini, Marco Salvioni, Massimo Venturini, Federica Cipriani, Luca Aldrighetti, Francesco De Cobelli
International Journal of Hyperthermia. 2020; 37(1): 542
[Pubmed] | [DOI]
174 miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance
Tao Han, Yue Zhang, Xiaodan Yang, Lei Han, Hengyu Li, Tingsong Chen, Zhendong Zheng
Molecular Therapy - Nucleic Acids. 2020; 19: 1073
[Pubmed] | [DOI]
175 MYB Proto-oncogene-like 1-TWIST1 Axis Promotes Growth and Metastasis of Hepatocellular Carcinoma Cells
Binhui Xie, Yao Liu, Zhenxian Zhao, Qingquan Liu, Xiaonong Wang, Yuankang Xie, Yanhong Liu, Yuwen Liu, Yan Yang, Jianting Long, Qiangsheng Dai, Heping Li
Molecular Therapy - Oncolytics. 2020; 18: 58
[Pubmed] | [DOI]
176 The blooming intersection of transcatheter hepatic artery chemoembolization and nanomedicine
Hu Chen, Hongwei Cheng, Wenying Wu, Dengfeng Li, Jingsong Mao, Chengchao Chu, Gang Liu
Chinese Chemical Letters. 2020; 31(6): 1375
[Pubmed] | [DOI]
177 A novel quinolinylmethyl substituted ethylenediamine compound exerts anti-cancer effects via stimulating the accumulation of reactive oxygen species and NO in hepatocellular carcinoma cells
Fujun Jin, Rongze Wang, Yexuan Zhu, Jingyi Chen, Wei Cao, Yiliang Wang, Yanting Wu, Xiaowei Song, Yunsheng Huang, Jun Dong, Zhe Ren
European Journal of Pharmacology. 2020; 885: 173497
[Pubmed] | [DOI]
178 Astragaloside IV suppresses development of hepatocellular carcinoma by regulating miR-150-5p/ß-catenin axis
Xiang Cui, Xiaoyan Jiang, Chunshan Wei, Yufeng Xing, Guangdong Tong
Environmental Toxicology and Pharmacology. 2020; 78: 103397
[Pubmed] | [DOI]
179 Differentially expressed mRNAs and lncRNAs shared between activated human hepatic stellate cells and nash fibrosis
Glenn S. Gerhard, Bethany Davis, Xiumei Wu, Amanda Hanson, Danielle Wilhelmsen, Ignazio S. Piras, Christopher D. Still, Xin Chu, Anthony T. Petrick, Johanna K. DiStefano
Biochemistry and Biophysics Reports. 2020; 22: 100753
[Pubmed] | [DOI]
180 Long noncoding RNA linc00467 plays an oncogenic role in hepatocellular carcinoma by regulating the miR-18a-5p/NEDD9 axis
Yuanwen Zheng, Peihua Nie, Shifeng Xu
Journal of Cellular Biochemistry. 2020; 121(5-6): 3135
[Pubmed] | [DOI]
181 Synthesis and in vitro bioactivity study of new hydrazide-hydrazones of 5-bromo-2-iodobenzoic acid
Lukasz Popiolek, Pawel Patrejko, Monika Gawronska-Grzywacz, Anna Biernasiuk, Anna Berecka-Rycerz, Dorota Natorska-Chomicka, Iwona Piatkowska-Chmiel, Anna Gumieniczek, Jaroslaw Dudka, Monika Wujec
Biomedicine & Pharmacotherapy. 2020; 130: 110526
[Pubmed] | [DOI]
182 The effects of hyperthermia on human hepatocellular carcinoma stem and mature cancer cells
David Sontag, David A. Miles, Julia Uhanova, Micah Grubert Van Iderstine, Jiaqi Yang, Gerald Y. Minuk
Annals of Hepatology. 2020; 19(3): 265
[Pubmed] | [DOI]
183 Pathways involved in viral oncogenesis: New perspectives from virus-host protein interactomics
Medi Kori, Kazim Yalcin Arga
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2020; 1866(10): 165885
[Pubmed] | [DOI]
184 CircRNA circ-0038718 promotes hepatocellular carcinoma progression through sponging miR-139-3p
Ranran Sun, Hua Li, Jianhao Li, Shen Shen, Guangying Cui, Gang Dong
Biochemical and Biophysical Research Communications. 2020; 533(4): 845
[Pubmed] | [DOI]
185 Supersaturated LFCS type III self-emulsifying delivery systems of sorafenib tosylate with improved biopharmaceutical performance: QbD-enabled development and evaluation
Teenu Sharma, Atul Jain, Ranjot Kaur, Sumant Saini, O P Katare, Bhupinder Singh
Drug Delivery and Translational Research. 2020; 10(4): 839
[Pubmed] | [DOI]
186 Genomic Landscape of HCC
Nia Adeniji, Renumathy Dhanasekaran
Current Hepatology Reports. 2020; 19(4): 448
[Pubmed] | [DOI]
187 Transcriptomic profiling of long non-coding RNAs in non-virus associated hepatocellular carcinoma
Lu Liu, Chen He, Haosheng Liu, Ganlu Wang, Zhiwu Lv, Yong Ni, Lisha Mou, Yongqiang Zhan, Jintao Liu
Cell Biochemistry and Biophysics. 2020; 78(4): 465
[Pubmed] | [DOI]
188 The Significance of HCV Viral Load in the Incidence of HCC: a Correlation Between Mir-122 and CCL2
Heba K. Nabih
Journal of Gastrointestinal Cancer. 2020; 51(2): 412
[Pubmed] | [DOI]
189 The Anticancer Efficacy of Platinum Azidothymidin on Hepatocellular Carcinoma Via Affecting the Telomerase and the BcL-2 Genes Expression
Abdolreza Sabokrouh, Fereshteh Atabi, Raghed Mohammed Jassem, Reza Mohammadi
Journal of Gastrointestinal Cancer. 2020; 51(3): 813
[Pubmed] | [DOI]
190 Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center
Brian Rutledge, Jenny Jan, Sindhuri Benjaram, Neha Sahni, Paul Naylor, Philip Philip, Murray Ehrinpreis, Milton Mutchnick
Journal of Gastrointestinal Cancer. 2020; 51(3): 972
[Pubmed] | [DOI]
191 Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Gabriel Schwartz, Julianne O. Darling, Malori Mindo, Lucia Damicis
Targeted Oncology. 2020; 15(4): 549
[Pubmed] | [DOI]
192 Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
Giulia Orsi, Francesco Tovoli, Vincenzo Dadduzio, Caterina Vivaldi, Oronzo Brunetti, Luca Ielasi, Fabio Conti, Giulia Rovesti, Laura Gramantieri, Mario Domenico Rizzato, Irene Pecora, Antonella Argentiero, Federica Teglia, Sara Lonardi, Francesca Salani, Alessandro Granito, Vittorina Zagonel, Giorgia Marisi, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Francesca Benevento, Alessandro Cucchetti, Fabio Piscaglia, Stefano Cascinu, Mario Scartozzi, Andrea Casadei-Gardini
Targeted Oncology. 2020; 15(6): 773
[Pubmed] | [DOI]
193 Diagnostische und prognostische Bedeutung des a-Feto-Proteins beim hepatozellulären Karzinom
Jendrik Becker-Assmann, Mohammad H. Fard-Aghaie, Alexandros Kantas, Georgios Makridis, Tim Reese, Kim C. Wagner, Jörg Petersen, Peter Buggisch, Axel Stang, Thomas von Hahn, Karl J. Oldhafer
Der Chirurg. 2020; 91(9): 769
[Pubmed] | [DOI]
194 Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction
Sarah Lechner, Matthew Yee, Berkeley N. Limketkai, Edward A. Pham
Digestive Diseases and Sciences. 2020; 65(3): 897
[Pubmed] | [DOI]
195 Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C–Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy
Mustafa Nazzal, Subhayan Sur, Robert Steele, Mousumi Khatun, Tapas Patra, Nancy Phillips, John Long, Ranjit Ray, Ratna B. Ray
Hepatology. 2020; 72(2): 379
[Pubmed] | [DOI]
196 A 4-gene prognostic signature predicting survival in hepatocellular carcinoma
Peng-Fei Chen, Qing-He Li, Li-Rong Zeng, Xue-Ying Yang, Pai-Lan Peng, Jian-Hua He, Bin Fan
Journal of Cellular Biochemistry. 2019; 120(6): 9117
[Pubmed] | [DOI]
197 Integrated mRNA-Seq and miRNA-Seq analysis of PLC?2-overexpressing hepatocarcinoma cells and identification of the associated miRNA-mRNA network
Xiaoguang Chen, Xuemin Zhu, Zhiguo Wei, Qiongxia Lv
Journal of Cellular Biochemistry. 2019; 120(12): 19878
[Pubmed] | [DOI]
198 “Preoperative prediction of tumor recurrence in HCC - A commentary on: Dynamic liver function is an independent predictor of recurrence-free survival after curative liver resection for HCC - A retrospective cohort study” (Int J Surg 2019; Sep 5. pii: S174
Daniel Heise, Ulf Peter Neumann
International Journal of Surgery. 2019; 71: 82
[Pubmed] | [DOI]
199 Hepatitis B as hepatocellular carcinoma (HCC) risk factor in the south region of Java, Indonesia
Nur Signa A Gumilas, Ika M Harini, Thianty Sylviningrum, Wahyu Djatmiko, Lantip Rujito
Journal of Physics: Conference Series. 2019; 1246(1): 012013
[Pubmed] | [DOI]
200 Noncoding RNAs Serve as Diagnosis and Prognosis Biomarkers for Hepatocellular Carcinoma
Chang Tan, Jingyi Cao, Lu Chen, Xiaochen Xi, Siqi Wang, Yumin Zhu, Liuqing Yang, Longteng Ma, Dong Wang, Jianhua Yin, Ti Zhang, Zhi John Lu
Clinical Chemistry. 2019; 65(7): 905
[Pubmed] | [DOI]
201 Role of Tie2, CD14, Angiopoietin as Angiogenetic Markers in Hepatocellular Carcinoma Complicating Hepatitis C Virus Infection
El-Zahraa M. Meghezel, Heba A. Ahmed, Ashraf A Askar, Emad Eldin Nabil, Ashraf Elyamany, Rada M. Grubovic
Journal of Hematology and Oncology Research. 2019; 3(2): 23
[Pubmed] | [DOI]
202 Theranostic liposomes as nanodelivered chemotherapeutics enhanced the microwave ablation of hepatocellular carcinoma
Qunfang Zhou, Kun Wang, Jianping Dou, Feng Cao, Fengyong Liu, Hongjun Yuan, Mengjuan Mu, Jinshun Xu, Dongyun Zhang, Xin Li, Jie Tian, Jie Yu, Ping Liang
Nanomedicine. 2019; 14(16): 2151
[Pubmed] | [DOI]
203 Proliferation of human hepatocellular carcinoma cells from surgically resected specimens under conditionally reprogrammed culture
Zhenglu Wang, Bowen Bi, Hongli Song, Lei Liu, Hong Zheng, Shusen Wang, Zhongyang Shen
Molecular Medicine Reports. 2019;
[Pubmed] | [DOI]
204 Knockdown of ACTA2-AS1 promotes liver cancer cell proliferation, migration and invasion
Ru-Jian Zhou, Hui-Zeng Lv
Molecular Medicine Reports. 2019;
[Pubmed] | [DOI]
205 The Role of Hepatitis C virus and Possible Risk factors in development of Hepatocellular carcinoma: 400 Patients based study
Fatema Abu-bakr Abdelmoez, Hala Mostafa Imam, Naglaa Kamal Idriss, Lobna Abdel Wahid, Wael Ahmed Abbas, Mohamed Abozaid Ali Abozaid, Hossam Mahmoud Abdelwahab
The Egyptian Journal of Internal Medicine. 2019; 31(1): 64
[Pubmed] | [DOI]
206 Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies
Mostafa MM El-Miligy, Samia M Rida, Fawzia A Ashour, Mona H Badr, Ehab M El-Bassiony, Maha A El-Demellawy, Ashraf M Omar
Future Science OA. 2018; 4(1): FSO252
[Pubmed] | [DOI]
207 Downregulation of YAP inhibits proliferation, invasion and increases cisplatin sensitivity in human hepatocellular carcinoma cells
Xiaoguang Wang, Bin Wu, Zhengxiang Zhong
Oncology Letters. 2018;
[Pubmed] | [DOI]
208 Immune Responses in the Liver
Paul Kubes, Craig Jenne
Annual Review of Immunology. 2018; 36(1): 247
[Pubmed] | [DOI]
209 Sonoporation by microbubbles as gene therapy approach against liver cancer
Luca Rinaldi, Veronica Folliero, Luciana Palomba, Carla Zannella, Rachele Isticato, Raffaele Di Francia, Massimiliano Berretta, Ilario de Sio, Luigi E. Adinolfi, Giancarlo Morelli, Secondo Lastoria, Lucia Altucci, Carlo Pedone, Massimiliano Galdiero, Gianluigi Franci
Oncotarget. 2018; 9(63): 32182
[Pubmed] | [DOI]
210 Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy
Yue Zhao, Timothy Wai Ho Shuen, Tan Boon Toh, Xue Ying Chan, Min Liu, Sue Yee Tan, Yong Fan, Hechuan Yang, Shridhar Ganpathi Lyer, Glenn Kunnath Bonney, Eva Loh, Kenneth Tou En Chang, Thiam Chye Tan, Weiwei Zhai, Jerry Kok Yen Chan, Edward Kai-Hua Chow, Cheng Ean Chee, Guan Huei Lee, Yock Young Dan, Pierce Kah-Hoe Chow, Han Chong Toh, Seng Gee Lim, Qingfeng Chen
Gut. 2018; 67(10): 1845
[Pubmed] | [DOI]
211 Interrogation of Antigen Display on Individual Vaccine Nanoparticles for Achieving Neutralizing Antibody Responses against Hepatitis C Virus
Joseph D. Bazzill, Lukasz J. Ochyl, Erick Giang, Shaun Castillo, Mansun Law, James J. Moon
Nano Letters. 2018; 18(12): 7832
[Pubmed] | [DOI]
212 New hydrazide-hydrazones and 1,3-thiazolidin-4-ones with 3-hydroxy-2-naphthoic moiety: Synthesis, in vitro and in vivo studies
Lukasz Popiolek, Iwona Piatkowska-Chmiel, Monika Gawronska-Grzywacz, Anna Biernasiuk, Magdalena Izdebska, Mariola Herbet, Marcin Sysa, Anna Malm, Jaroslaw Dudka, Monika Wujec
Biomedicine & Pharmacotherapy. 2018; 103: 1337
[Pubmed] | [DOI]


Previous article  Next article
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)  

  In this article
Pathogenesis of ...
Article Tables

 Article Access Statistics
    PDF Downloaded45    
    Comments [Add]    
    Cited by others 212    

Recommend this journal